# 2026年1月11日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 用于靶向膜穿透及胞质货物递送的噬菌体模拟DNA折纸针状结构

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41517839)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41517839
**DOI：** 10.1002/advs.202512844

### 第一部分 原文与翻译

**英文原标题：** Bacteriophage-Mimetic DNA Origami Needle for Targeted Membrane Penetration and Cytosolic Cargo Delivery.

> **英文摘要：**
> Inspired by the natural ability of bacteriophages to deliver genetic material directly into host cells, we employed a bottom-up approach to construct a multifunctional synthetic DNA origami needle-like structure. This origami is functionalized with trastuzumab antibodies, cholesterol, protective polymers, and two dyes, which together enable selective targeting and insertion into SKBR3 cancer cells. A disulfide-linked dye payload was attached to the apex of the needle, allowing controlled release in the cytoplasm triggered by the high intracellular glutathione concentration. Real-time tracking of the payload confirmed both successful targeting of the origami structure and subsequent direct cytosolic delivery. By mimicking fundamental mechanisms of bacteriophages, we propose that this artificial needle structure can serve as a prototypical device for the targeted delivery of small-molecule drugs directly into the cytosol.

> **中文摘要：**
> 受噬菌体将遗传物质直接递送至宿主细胞的天然能力启发，我们采用自下而上的方法构建了一种多功能合成DNA折纸针状结构。该折纸结构被功能化修饰了曲妥珠单抗抗体、胆固醇、保护性聚合物和两种染料，这些组分共同实现了对SKBR3癌细胞的选择性靶向和插入。一个通过二硫键连接的染料载荷被附着在针的顶端，使其能够在细胞内高浓度谷胱甘肽的触发下在细胞质中实现可控释放。对载荷的实时追踪证实了折纸结构成功靶向以及随后的直接胞质递送。通过模拟噬菌体的基本机制，我们提出这种人工针状结构可以作为一种原型装置，用于将小分子药物直接靶向递送至细胞质。

### 第二部分 AI 大师评价

本研究旨在开发一种仿噬菌体DNA折纸针，以实现对癌细胞的靶向膜穿透及胞质递送。其核心方法是通过自下而上的DNA折纸技术构建多功能针状结构，并修饰靶向分子、膜锚定物及响应性连接载荷。研究发现，该结构能特异性靶向SKBR3细胞，并在胞内高谷胱甘肽环境下释放载荷，实现了实时验证的直接胞质递送。其创新性在于巧妙融合了仿生设计、DNA纳米技术与刺激响应释放机制，为小分子药物的精准胞内递送提供了新范式；局限性在于目前仅为概念验证研究，其体内稳定性、递送效率及潜在免疫原性有待进一步评估。

---

## 2. Neddylation靶向并稳定NLRP3以增强炎症小体介导的结肠炎和情绪障碍。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41514502)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41514502
**DOI：** 10.1002/advs.202505906

### 第一部分 原文与翻译

**英文原标题：** Neddylation Targets and Stabilizes NLRP3 to Augment Inflammasome-Mediated Colitis and Mood Disorder.

> **英文摘要：**
> The activation of NLRP3 inflammasome contributes to the development of numerous chronic inflammatory diseases, including ulcerative colitis and stress-induced anxiety. Recent studies have revealed that NLRP3 K48-linked ubiquitination by several E3 ligases, including Trim31, leads to degradation. Neddylation is a process highly similar to ubiquitination by covalently conjugating NEDD8 to lysines in specific substrate proteins. Neddylation of substrate proteins alters their subcellular localization, stability, and activity. The role of neddylation in the NLRP3 inflammasome remains elusive. Here, we report that neddylation promotes the activation of the NLRP3 inflammasome in macrophages. Myeloid deficiency of UBA3, the catalytic subunit of the NEDD8-activating enzyme (NAE), renders mice resistant to dextran sodium sulfate-induced colitis. Inducible Uba3 deletion in microglia mitigates psychological stress-induced anxiety-like behavior. Neddylation blockade led to a reduced protein level of NLRP3 without affecting its mRNA level. Further exploration revealed that NLRP3 undergoes neddylation at K287 with Ube2M as the E2 and Smurf2 as an E3, respectively. NLRP3 neddylation hinders its interaction with Trim31 and thereby inhibits its K48-linked ubiquitination and subsequent degradation. MLN4924, a potent compound NAE inhibitor in phase 1/2/3 clinical trials for cancers, alleviates psychological stress-induced NLRP3 inflammasome activation, microglia inflammatory activation, and anxiety-like behavior, suggesting novel clinical activity of MLN4924.

> **中文摘要：**
> NLRP3炎症小体的激活促进了许多慢性炎症性疾病的发展，包括溃疡性结肠炎和应激诱导的焦虑。最近的研究表明，包括Trim31在内的几种E3连接酶介导的NLRP3 K48连接泛素化会导致其降解。Neddylation是一种与泛素化高度相似的过程，通过将NEDD8共价连接到特定底物蛋白的赖氨酸上。底物蛋白的neddylation会改变其亚细胞定位、稳定性和活性。Neddylation在NLRP3炎症小体中的作用尚不清楚。在此，我们报道neddylation促进了巨噬细胞中NLRP3炎症小体的激活。髓系细胞中NEDD8激活酶（NAE）催化亚基UBA3的缺失，使小鼠对葡聚糖硫酸钠诱导的结肠炎产生抵抗。在小胶质细胞中诱导性敲除Uba3可减轻心理应激诱导的焦虑样行为。阻断neddylation导致NLRP3蛋白水平降低，但不影响其mRNA水平。进一步探索发现，NLRP3在K287位点发生neddylation，其中Ube2M作为E2，Smurf2作为E3。NLRP3的neddylation阻碍了其与Trim31的相互作用，从而抑制了其K48连接泛素化及随后的降解。MLN4924是一种强效的NAE抑制剂化合物，目前正处于针对癌症的1/2/3期临床试验中，它能减轻心理应激诱导的NLRP3炎症小体激活、小胶质细胞炎症激活和焦虑样行为，这提示了MLN4924新的临床活性。

### 第二部分 AI 大师评价

本研究旨在阐明neddylation修饰在NLRP3炎症小体调控及炎症相关疾病中的作用机制。研究通过构建髓系细胞和小胶质细胞特异性基因敲除小鼠模型，结合分子生物学手段，发现neddylation通过Ube2M/Smurf2复合物在NLRP3的K287位点进行修饰，从而竞争性抑制其被Trim31介导的K48泛素化降解，最终稳定NLRP3蛋白并促进其炎症小体激活。其创新性在于首次揭示了neddylation稳定NLRP3蛋白的新机制，并将NLRP3炎症小体激活与结肠炎、焦虑样行为联系起来，同时为已进入临床试验的抗癌药物MLN4924（NAE抑制剂）在炎症性疾病中的潜在应用提供了新的理论依据。局限性在于，研究主要基于小鼠模型和细胞实验，其在人体内的确切作用及MLN4924治疗相关疾病的临床转化效果仍需进一步验证。

---

## 3. 肝细胞BPGM通过诱导RET乳酸化修饰和巨噬细胞重编程促进肝细胞癌的肿瘤发生。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41514495)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41514495
**DOI：** 10.1002/advs.202518180

### 第一部分 原文与翻译

**英文原标题：** Hepatocyte BPGM Induces RET Lactylation and Macrophage Reprogramming to Promote Tumorigenesis in Hepatocellular Carcinoma.

> **英文摘要：**
> Aerobic glycolysis is a hallmark of cancer, yet the role of the key glycolytic enzyme bisphosphoglycerate mutase (BPGM) in hepatocellular carcinoma (HCC) progression remains unclear. Here, clinical sample analyses revealed that BPGM expression was upregulated in HCC tissues and associated with poor prognosis. Hepatocyte-specific Bpgm knockout significantly attenuated DEN-induced HCC development in mice. Spatial transcriptomics and single-cell RNA sequencing revealed that hepatocyte-specific Bpgm knockout reduced the monocyte/macrophage infiltration and decreased M2 polarization of tumor-associated macrophages. Additionally, BPGM overexpression promoted the proliferation and migration of HCC cells and enhanced intracellular lactate accumulation. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) identified ret proto-oncogene (RET) as a downstream effector that mediated the effects of BPGM on HCC cells. BPGM promoted P300-mediated lactylation of RET at lysine 549 (K549), which competitively inhibited its ubiquitination, thereby preventing RET protein degradation and enhancing its stability. BPGM in HCC cells also induced both histone lactylation and M2 polarization of macrophages by lactate secretion. This study revealed that BPGM in hepatocytes could enhance RET expression via increasing its lactylation in malignant cells and promote M2 polarization of macrophages, both of which contributed to HCC progression. These findings established that BPGM could act as a potential therapeutic target for HCC.

> **中文摘要：**
> 有氧糖酵解是癌症的一个标志，但关键糖酵解酶二磷酸甘油酸变位酶（BPGM）在肝细胞癌（HCC）进展中的作用尚不清楚。临床样本分析显示，BPGM在HCC组织中表达上调，并与不良预后相关。肝细胞特异性Bpgm敲除显著减弱了DEN诱导的小鼠HCC发展。空间转录组学和单细胞RNA测序显示，肝细胞特异性Bpgm敲除减少了单核细胞/巨噬细胞浸润，并降低了肿瘤相关巨噬细胞的M2极化。此外，BPGM过表达促进了HCC细胞的增殖和迁移，并增强了细胞内乳酸积累。液相色谱-串联质谱（LC-MS/MS）鉴定出ret原癌基因（RET）是介导BPGM对HCC细胞作用的下游效应因子。BPGM促进了P300介导的RET在赖氨酸549（K549）位点的乳酸化修饰，这种修饰竞争性抑制了其泛素化，从而阻止了RET蛋白降解并增强了其稳定性。HCC细胞中的BPGM还通过分泌乳酸诱导了组蛋白乳酸化修饰和巨噬细胞的M2极化。本研究揭示，肝细胞中的BPGM可通过增加恶性细胞中RET的乳酸化修饰来增强其表达，并促进巨噬细胞的M2极化，这两者共同促进了HCC的进展。这些发现确立了BPGM可作为HCC的潜在治疗靶点。

### 第二部分 AI 大师评价

本研究旨在阐明糖酵解酶BPGM在肝细胞癌进展中的具体作用机制。通过整合临床样本分析、基因工程小鼠模型、空间转录组学、单细胞测序和蛋白质组学（LC-MS/MS）等多层次技术，研究揭示了BPGM通过双重机制驱动HCC：一方面，在肿瘤细胞内通过P300介导RET蛋白K549位点乳酸化，抑制其泛素化降解，从而稳定RET原癌蛋白；另一方面，通过分泌乳酸诱导肿瘤相关巨噬细胞向M2型极化，重塑免疫抑制微环境。其创新性在于首次将BPGM的代谢功能与RET蛋白的乳酸化修饰及肿瘤免疫调控直接联系起来，为HCC提供了新的潜在治疗靶点。局限性在于，研究主要基于临床前模型，BPGM作为治疗靶点的成药性及其在人体内的具体调控网络仍需进一步验证。

---

## 4. 肽-适配体偶联物与干细胞来源外泌体通过免疫亲和模拟组装构建层级微凝胶用于脊髓损伤修复。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41514481)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41514481
**DOI：** 10.1002/advs.202519701

### 第一部分 原文与翻译

**英文原标题：** Immunoaffinity-Mimetic Assembly of Peptide-Aptamer Conjugates and Stem Cell-Derived Exosomes into Hierarchical Microgels for Spinal Cord Injury Repair.

> **英文摘要：**
> Mesenchymal stem cell-derived exosomes (MSC-Exo) containing various paracrine mediators have recently been recognized to promote functional recovery of spinal cord injury (SCI). However, their biomedical applications are hindered by limited possibilities for specific integration within the delivery systems. In this study, inspired by antibody-antigen binding, we present an unprecedented assembly strategy that leverages immunoaffinity-mimetic interactions of peptide-aptamer (Peptide-Apt) conjugates targeting CD63 markers on MSC-Exo, yielding a hierarchical microstructure to enhance SCI repair. The conjugate, serving as the microgel scaffold, is synthesized by grafting azide-modified Apt onto poly(propargyl cysteine-co-γ-propargyl--glutamate). It exhibits excellent antioxidant capability to mitigate oxidative stress and immune responses at the injury site. In addition, this conjugate constrains the tethered MSC-Exo within the lesion site during administration, yet its nuclease susceptibility allows for the release of MSC-Exo to promote the proliferation and migration of neural stem cells and to direct their differentiation into neurons rather than astrocytes. These synergistic effects ultimately enhance neuroregeneration, thereby promoting the motor function recovery of SCI mice. Our work represents a pioneering effort in harnessing the specificity of immunoaffinity-mimetic interactions between aptamers and biomacromolecules for the high-performance assembly of chemically vulnerable biologics, facilitating widespread applications across materials science and life science.

> **中文摘要：**
> 间充质干细胞来源的外泌体（MSC-Exo）含有多种旁分泌介质，近年来被认为能促进脊髓损伤（SCI）的功能恢复。然而，其在递送系统中特异性整合的可能性有限，阻碍了其生物医学应用。本研究受抗体-抗原结合的启发，提出了一种前所未有的组装策略，该策略利用靶向MSC-Exo上CD63标记物的肽-适配体（Peptide-Apt）偶联物的免疫亲和模拟相互作用，构建出一种层级微结构以增强SCI修复。该偶联物作为微凝胶支架，是通过将叠氮修饰的适配体接枝到聚（炔丙基半胱氨酸-co-γ-炔丙基-谷氨酸）上合成的。它表现出优异的抗氧化能力，可减轻损伤部位的氧化应激和免疫反应。此外，该偶联物在给药期间能将束缚的MSC-Exo限制在病变部位，但其对核酸酶的敏感性又允许MSC-Exo释放，从而促进神经干细胞的增殖和迁移，并引导其分化为神经元而非星形胶质细胞。这些协同效应最终增强了神经再生，从而促进了SCI小鼠的运动功能恢复。我们的工作开创性地利用了适配体与生物大分子之间免疫亲和模拟相互作用的特异性，实现了对化学性质脆弱的生物制剂的高性能组装，为材料科学和生命科学的广泛应用提供了便利。

### 第二部分 AI 大师评价

本研究旨在解决间充质干细胞外泌体（MSC-Exo）在脊髓损伤修复中靶向递送和可控释放的难题。其核心创新在于，受抗体-抗原结合启发，设计了一种肽-适配体偶联物作为微凝胶支架，通过模拟免疫亲和相互作用特异性捕获MSC-Exo，构建了具有层级结构的微凝胶递送系统。该系统不仅实现了外泌体在损伤部位的靶向滞留和响应性释放，还兼具抗氧化功能，协同促进了神经再生和运动功能恢复。该策略巧妙地将分子识别、生物材料工程与细胞治疗相结合，为脆弱生物大分子的高效组装与应用开辟了新途径，但其体内长期安全性与临床转化潜力仍需进一步验证。

---

## 5. 解锁非编码RNA的潜力：迈向精准肿瘤学中的实时癌症监测。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41514444)
**期刊：** Molecular cancer
**PMID：** 41514444
**DOI：** 10.1186/s12943-025-02536-y

### 第一部分 原文与翻译

**英文原标题：** Unlocking the power of non-coding RNAs: toward real-time cancer monitoring in precision oncology.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文旨在探讨非编码RNA在精准肿瘤学中作为实时监测工具的潜力。其核心目的是阐述如何利用非编码RNA的动态变化，实现对癌症进展和治疗反应的实时追踪。文章聚焦于方法学层面，可能涉及对循环非编码RNA等生物标志物的检测与分析技术。其创新性在于将非编码RNA的研究从基础机制探索推向临床实时监测的应用前沿，为个体化治疗决策提供动态依据。然而，由于摘要缺失，其具体技术路径、验证数据及当前面临的临床转化局限性（如标准化、特异性等）尚不明确。

---

## 6. 长读长基因组测序提升儿童神经系统疾病的诊断能力。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41514368)
**期刊：** Genome medicine
**PMID：** 41514368
**DOI：** 10.1186/s13073-025-01596-5

### 第一部分 原文与翻译

**英文原标题：** Long-read genome sequencing enhances diagnostics of pediatric neurological disorders.

> **英文摘要：**
> BACKGROUND: Singleton short-read genome sequencing (GS) is increasingly used as a first-line genetic test for childhood neurological disorders (such as intellectual disability, neurodevelopmental delay, motor delay, and hypotonia) with diagnostic yields from 26 to 35%, typically involving a mix of single nucleotide variants and small insertions/deletions (SNV/INDELs), structural variants (SVs), and short tandem repeats (STRs). Long-read GS is emerging as an attractive alternative, offering a more comprehensive assessment of the genome, but its utility still needs to be systematically evaluated in a clinical diagnostic setting. METHODS: We prospectively included 100 children and adolescents (≤ 20 years) with neurological disorders, newly referred for genetic testing. Routine DNA was used for singleton standard clinical short-read GS in parallel with long-read GS (Oxford Nanopore Technologies). In addition to comprehensive variant calling, long-read GS data was also phased and underwent methylation analysis. Variant interpretation was restricted to in-silico gene panels targeting either intellectual disability (1,568 genes) or neuromuscular disorders (1,035 genes) depending on the clinical presentation. RESULTS: The long-read GS generated an average of 111 GB data per sample, with a median read-length of 5 kb and average N50 of 16 kb; resulting in an average coverage of 34X. Short-read and long-read GS identified the same 29% diagnostic yield, including SNV/INDELs (n = 18), SVs (n = 9), STRs (n = 1), and uniparental disomy (n = 1). Long-read GS provided additional diagnostic value in 13 cases involving 17 distinct variants, including phasing of SMN1 and biallelic SNVs/INDELs in autosomal recessive genes, accurate determination of STR length and sequence as well as detailed structural characterization of SVs. Of note, an unbalanced translocation, der(14)t(8;14)(p11.2;p23.1), required de novo assembly and T2T-CHM13 alignment to resolve the breakpoint junctions. Furthermore, long-read GS detected disease-associated aberrant methylation patterns in the Prader-Willi region and across an FMR1 expansion. CONCLUSIONS: In a clinical diagnostic setting, long-read GS proved to be a streamlined, first-line test, capturing the full spectrum of disease-causing variants, reducing the need for follow-up testing and enabling more precise interpretation. While the overall diagnostic yield may be comparable to that of short-read approaches, long-read GS offers significant added value across multiple variant types.

> **中文摘要：**
> 背景：单样本短读长基因组测序（GS）越来越多地被用作儿童神经系统疾病（如智力障碍、神经发育迟缓、运动迟缓和肌张力减退）的一线遗传学检测，其诊断率在26%至35%之间，通常涉及单核苷酸变异和小片段插入/缺失（SNV/INDELs）、结构变异（SVs）以及短串联重复序列（STRs）的混合。长读长GS正成为一种有吸引力的替代方案，可提供更全面的基因组评估，但其在临床诊断环境中的效用仍需系统评估。方法：我们前瞻性地纳入了100名新近转诊进行基因检测的神经系统疾病儿童和青少年（≤20岁）。使用常规DNA同时进行单样本标准临床短读长GS和长读长GS（牛津纳米孔技术）。除了全面的变异检测外，长读长GS数据还进行了单倍型定相和甲基化分析。变异解释仅限于针对临床表现的、靶向智力障碍（1,568个基因）或神经肌肉疾病（1,035个基因）的计算机基因组合。结果：长读长GS平均每个样本产生111 GB数据，中位读长为5 kb，平均N50为16 kb；平均覆盖度为34X。短读长和长读长GS均识别出相同的29%诊断率，包括SNV/INDELs（n=18）、SVs（n=9）、STRs（n=1）和单亲二体（n=1）。长读长GS在13个病例中提供了额外的诊断价值，涉及17个不同的变异，包括SMN1基因的单倍型定相、常染色体隐性遗传基因中双等位基因SNV/INDELs的定相、STR长度和序列的精确测定以及SVs的详细结构表征。值得注意的是，一个不平衡易位，der(14)t(8;14)(p11.2;p23.1)，需要通过从头组装和T2T-CHM13比对来解析断点连接处。此外，长读长GS在Prader-Willi区域和FMR1基因扩增区域检测到了与疾病相关的异常甲基化模式。结论：在临床诊断环境中，长读长GS被证明是一种简化的一线检测方法，能够捕获全谱系的致病性变异，减少后续检测的需求，并实现更精确的解读。虽然总体诊断率可能与短读长方法相当，但长读长GS在多种变异类型上提供了显著的附加价值。

### 第二部分 AI 大师评价

本研究旨在系统评估长读长基因组测序在儿童神经系统疾病临床诊断中的效用。研究前瞻性纳入100名患者，平行比较了长读长与短读长测序的诊断效能。核心发现是，虽然两者总体诊断率（29%）相同，但长读长测序在13%的病例中提供了关键附加诊断信息，特别是在单倍型定相、重复序列精确测定、复杂结构变异解析及甲基化分析方面，实现了更全面的变异检测与解读。其创新性在于首次在真实临床诊断场景中，系统性地证明了长读长测序作为一线检测方法的综合优势，但局限性在于变异解读仍局限于预设的基因组合，可能遗漏组合外的致病发现。

---

## 7. PBRM1缺失通过表观遗传调控PBRM1-KDM5C-IL6轴重塑ccRCC的免疫抑制微环境。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41514194)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41514194
**DOI：** 10.1002/advs.202512627

### 第一部分 原文与翻译

**英文原标题：** PBRM1 Deficiency Reshapes an Immune Suppressive Microenvironment Through Epigenetic Tuning of PBRM1-KDM5C-IL6 Axis in ccRCC.

> **英文摘要：**
> Polybromo 1 (PBRM1) ranks as the second most commonly mutated gene in clear cell renal cell carcinoma (ccRCC), while its role in immune escape remains elusive. We developed a PBRM1-knockout mice model to perform single-cell RNA sequencing, which demonstrated a substantial population of immunosuppressive tumor-associated macrophages (TAMs) in the spontaneous tumor, with consistent results from an orthotopic renal tumor mice model. Multiplex immunohistochemistry of clinical samples revealed that PBRM1-deficient tumors exhibited increased M2 TAMs in both stroma and parenchyma, while CD8 T cells were restricted to the stroma. M2 TAMs and cancer-associated fibroblasts (CAFs) interacted to construct a tumor immune barrier, preventing CD8 T cell infiltration. Mechanistically, PBRM1 modulated interleukin-6 (IL-6) expression by recruiting lysine demethylase 5C (KDM5C), thereby orchestrating M2 polarization of TAMs. Blocking IL-6 synergistically augmented the antitumor efficacy of anti-PD-1 therapy. Our findings revealed a PBRM1-KDM5C-IL-6 axis that influenced antitumor immunity, indicating a potential immunotherapeutic strategy in PBRM1-deficient ccRCC.

> **中文摘要：**
> 多溴蛋白1（PBRM1）是透明细胞肾细胞癌（ccRCC）中第二常见的突变基因，但其在免疫逃逸中的作用尚不明确。我们构建了PBRM1敲除小鼠模型并进行单细胞RNA测序，结果显示自发性肿瘤中存在大量免疫抑制性肿瘤相关巨噬细胞（TAMs），原位肾肿瘤小鼠模型也得到了一致的结果。临床样本的多重免疫组化分析显示，PBRM1缺陷的肿瘤在间质和实质中均表现出M2型TAMs增多，而CD8 T细胞则被限制在间质中。M2型TAMs与癌症相关成纤维细胞（CAFs）相互作用，构建了肿瘤免疫屏障，阻止了CD8 T细胞的浸润。从机制上讲，PBRM1通过招募赖氨酸去甲基化酶5C（KDM5C）来调节白细胞介素-6（IL-6）的表达，从而调控TAMs向M2型极化。阻断IL-6可协同增强抗PD-1疗法的抗肿瘤效果。我们的研究揭示了一条影响抗肿瘤免疫的PBRM1-KDM5C-IL-6轴，为PBRM1缺陷型ccRCC指明了一种潜在的免疫治疗策略。

### 第二部分 AI 大师评价

本研究旨在阐明ccRCC中高频突变基因PBRM1缺失如何重塑免疫抑制微环境。研究者创新性地结合了PBRM1敲除小鼠模型、单细胞测序、临床样本验证及机制探索，系统揭示了PBRM1通过招募KDM5C表观遗传调控IL-6表达，进而驱动TAMs M2极化并与CAFs协同形成免疫屏障的核心机制。其核心发现是定义了PBRM1-KDM5C-IL-6这一新的调控轴，并提出了靶向IL-6联合抗PD-1治疗的潜在策略，为PBRM1缺陷型ccRCC的免疫治疗提供了新思路。局限性在于，研究主要基于临床前模型，其转化至临床的有效性及安全性仍需进一步验证，且对轴中其他潜在下游效应分子的探索可能不足。

---

## 8. 长期细颗粒物暴露下，POMC神经元中功能失调的TRIM31引发下丘脑损伤及外周代谢紊乱。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41514067)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41514067
**DOI：** 10.1002/advs.202508458

### 第一部分 原文与翻译

**英文原标题：** Dysfunctional TRIM31 of POMC Neurons Provokes Hypothalamic Injury and Peripheral Metabolic Disorder under Long-Term Fine Particulate Matter Exposure.

> **英文摘要：**
> Particulate matter ≤2.5 µm (PM) elevates risks of neurological and chronic metabolic diseases, but the underlying mechanisms linking PM-induced central nervous system (CNS) injury to metabolic dysfunction remain unclear. Hypothalamic pro-opiomelanocortin-expressing (POMC+) neurons regulate systemic metabolic homeostasis, and tripartite motif-containing protein 31 (TRIM31) modulates inflammation and metabolism. Here, we investigated whether TRIM31 in POMC+ neurons mediates PM-induced hypothalamic injury and peripheral metabolic disorders in mice subjected to 24-week PM exposure. TRIM31 knockout in POMC neurons (POMCTRIM31) exacerbated PM-;induced increases in mean blood pressure and fat weight, liver weight reduction, adipocyte hypertrophy, hepatic lipid deposition, energy expenditure abnormalities and insulin resistance. It also aggravated hypothalamic damage (downregulated NeuN, POMC and MC4R) and amplified neuroinflammation and oxidative stress. Conversely, AAV-mediated TRIM31 overexpression in POMC neurons alleviated these pathological phenotypes. In vitro, TRIM31 deletion promoted reactive oxygen species (ROS) and inflammation in PM-challenged hypothalamic neurons and microglia, while TRIM31 overexpression exerted opposite effects; microglial TRIM31 depletion exacerbated neuronal death via conditioned medium. Mechanistically, TRIM31 directly interacted with Nrf2, enhancing its K63-linked polyubiquitination and reducing K48-linked polyubiquitination to activate Nrf2 signaling, which was required for TRIM31-mediated attenuation of neuronal death and inflammation under PM2.5 stress. Collectively, our findings identify the TRIM31/Nrf2 axis as a key molecular switch governing POMC neuronal loss, hypothalamic injury and consequent peripheral metabolic disorders triggered by long-term PM exposure.

> **中文摘要：**
> 粒径≤2.5微米的颗粒物（PM）会增加神经系统和慢性代谢性疾病的风险，但PM诱导的中枢神经系统损伤与代谢功能障碍之间的潜在联系机制尚不清楚。下丘脑表达阿片黑素促皮质激素原（POMC+）的神经元调节全身代谢稳态，而含三联基序蛋白31（TRIM31）可调节炎症和代谢。本研究探讨了在经历24周PM暴露的小鼠中，POMC+神经元中的TRIM31是否介导了PM诱导的下丘脑损伤和外周代谢紊乱。在POMC神经元中敲除TRIM31（POMCTRIM31）加剧了PM诱导的平均血压和脂肪重量增加、肝脏重量减轻、脂肪细胞肥大、肝脏脂质沉积、能量消耗异常和胰岛素抵抗。它还加重了下丘脑损伤（NeuN、POMC和MC4R表达下调）并放大了神经炎症和氧化应激。相反，AAV介导的POMC神经元TRIM31过表达减轻了这些病理表型。在体外，TRIM31缺失促进了PM刺激的下丘脑神经元和小胶质细胞中的活性氧（ROS）和炎症，而TRIM31过表达则产生相反效果；小胶质细胞TRIM31缺失通过条件培养基加剧了神经元死亡。机制上，TRIM31直接与Nrf2相互作用，增强其K63连接的多聚泛素化并减少K48连接的多聚泛素化，从而激活Nrf2信号通路，这对于TRIM31介导的、在PM2.5应激下减轻神经元死亡和炎症是必需的。总之，我们的研究结果确定了TRIM31/Nrf2轴是控制长期PM暴露引发的POMC神经元丢失、下丘脑损伤及随之而来的外周代谢紊乱的关键分子开关。

### 第二部分 AI 大师评价

本研究旨在阐明长期细颗粒物（PM2.5）暴露导致外周代谢紊乱的中枢神经机制，聚焦于下丘脑POMC神经元及其表达的TRIM31蛋白。研究通过体内基因敲除/过表达、体外细胞模型及分子机制探索，系统揭示了TRIM31通过调控Nrf2的泛素化修饰激活其信号通路，从而减轻PM2.5诱导的神经元损伤、神经炎症和氧化应激，最终影响外周代谢表型。其创新性在于首次将TRIM31/Nrf2轴确立为连接环境暴露、下丘脑损伤与全身代谢失调的关键分子桥梁，为相关疾病的干预提供了新靶点；局限性在于主要基于动物模型，其在人体中的普适性及临床转化价值有待进一步验证。

---

## 9. UFMylation的机制基础与细胞功能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41514062)
**期刊：** Nature reviews. Molecular cell biology
**PMID：** 41514062
**DOI：** 10.1038/s41580-025-00944-y

### 第一部分 原文与翻译

**英文原标题：** The mechanistic basis and cellular functions of UFMylation.

> **英文摘要：**
> UFMylation is a ubiquitin-like post-translational modification that has a central role in ribosome-associated quality control at the endoplasmic reticulum (ER-RQC). Through a dedicated enzymatic cascade, UFM1 is conjugated to select substrates, notably the 60S ribosomal subunit protein RPL26, to maintain endoplasmic reticulum and ribosomal integrity under cellular stress. This Review focuses on the structural and mechanistic basis of UFMylation in ER-RQC and its contribution to proteostasis. Although recent studies have identified a growing number of putative UFM1-modified proteins across diverse cellular pathways, the physiological importance of many of these substrates remains unclear. We highlight both the emerging functional breadth of UFMylation and the need for caution in interpreting substrate relevance. UFMylation is increasingly linked to disease, including neurodevelopmental disorders and cancer, underscoring its biological importance. Together, these findings position UFMylation as a key regulatory system connecting endoplasmic reticulum function to broader stress responses.

> **中文摘要：**
> UFMylation是一种类泛素化翻译后修饰，在内质网核糖体相关质量控制（ER-RQC）中发挥核心作用。通过一个专门的酶促级联反应，UFM1被共价连接到特定的底物上，特别是60S核糖体亚基蛋白RPL26，以在细胞应激下维持内质网和核糖体的完整性。本综述聚焦于UFMylation在ER-RQC中的结构和机制基础及其对蛋白质稳态的贡献。尽管近期研究已发现越来越多的推定UFM1修饰蛋白存在于多种细胞通路中，但许多这些底物的生理重要性仍不清楚。我们既强调了UFMylation日益显现的功能广度，也指出了在解释底物相关性时需要保持谨慎。UFMylation与疾病的关联日益增多，包括神经发育障碍和癌症，这凸显了其生物学重要性。总之，这些发现将UFMylation定位为一个连接内质网功能与更广泛应激反应的关键调控系统。

### 第二部分 AI 大师评价

本文是一篇综述，旨在系统阐述UFMylation修饰的分子机制、细胞功能及其在疾病中的意义。核心目的是阐明UFMylation在内质网核糖体质量控制（ER-RQC）中的结构基础与作用机制，并探讨其对维持蛋白质稳态的贡献。其创新性在于整合了最新的结构生物学发现与功能研究，揭示了UFMylation作为一种关键调控系统，将内质网功能与细胞应激反应相连接。然而，文章也明确指出当前研究的局限性，即尽管已鉴定出大量潜在底物，但其具体的生理功能与病理相关性仍需更严谨的实验验证，这为未来研究指明了方向。

---

## 10. Suvemcitug联合化疗治疗铂类耐药复发性卵巢癌女性患者：SCORES随机、双盲、III期试验。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41514054)
**期刊：** Nature cancer
**PMID：** 41514054
**DOI：** 10.1038/s43018-025-01085-z

### 第一部分 原文与翻译

**英文原标题：** Suvemcitug plus chemotherapy in women with platinum-resistant recurrent ovarian cancer: the SCORES randomized, double-blinded, phase 3 trial.

> **英文摘要：**
> In the SCORES study ( NCT04908787 ), women with ovarian cancer that progressed within 6 months after completing platinum-based therapy were randomized (2:1) to receive suvemcitug (1.5 mg kg), an antibody to vascular endothelial growth factor or placebo every 2 weeks, with chemotherapy (paclitaxel, topotecan or PEGylated liposomal doxorubicin). The primary endpoint was progression-free survival (PFS). The key secondary endpoint was overall survival (OS). Other secondary endpoints included objective response rate, disease control rate, duration of response, quality of life, safety, pharmacokinetics and antidrug antibodies. Between June 5, 2021 and October 11, 2024, 421 participants were randomized (49.4% and 49.4% previously exposed to antiangiogenic agents and poly(ADP-ribose) polymerase inhibitors, respectively). Median PFS was 5.5 and 2.7 months in the suvemcitug and placebo arms, respectively (hazard ratio: 0.46, 95% confidence interval (CI): 0.35-0.60, P < 0.001), meeting the primary endpoint. Median OS was 15.3 versus 14.0 months, respectively (hazard ratio: 0.77, 95% CI: 0.60-0.99, P = 0.03). Decreased neutrophil count and decreased white blood cell count were the most common grade ≥3 treatment-emergent adverse events (TEAEs) in the suvemcitug arm. No suvemcitug-related grade 5 TEAE occurred. In conclusion, the addition of suvemcitug to chemotherapy significantly improved PFS and OS, with tolerable toxicities.

> **中文摘要：**
> 在SCORES研究（NCT04908787）中，将完成铂类治疗后6个月内进展的卵巢癌女性患者按2:1比例随机分组，分别接受血管内皮生长因子抗体suvemcitug（1.5 mg/kg）或安慰剂治疗，每两周一次，联合化疗（紫杉醇、拓扑替康或聚乙二醇化脂质体多柔比星）。主要终点是无进展生存期（PFS）。关键次要终点是总生存期（OS）。其他次要终点包括客观缓解率、疾病控制率、缓解持续时间、生活质量、安全性、药代动力学和抗药抗体。2021年6月5日至2024年10月11日期间，共421名参与者被随机分组（分别有49.4%和49.4%的患者既往接受过抗血管生成药物和聚（ADP-核糖）聚合酶抑制剂治疗）。Suvemcitug组和安慰剂组的中位PFS分别为5.5个月和2.7个月（风险比：0.46，95%置信区间（CI）：0.35-0.60，P < 0.001），达到了主要终点。中位OS分别为15.3个月和14.0个月（风险比：0.77，95% CI：0.60-0.99，P = 0.03）。在suvemcitug组中，中性粒细胞计数减少和白细胞计数减少是最常见的≥3级治疗期间出现的不良事件（TEAEs）。未发生与suvemcitug相关的5级TEAE。总之，在化疗基础上加用suvemcitug显著改善了PFS和OS，且毒性可耐受。

### 第二部分 AI 大师评价

本研究是一项针对铂类耐药复发性卵巢癌的关键III期临床试验，旨在评估新型抗血管内皮生长因子抗体suvemcitug联合化疗的疗效与安全性。研究设计严谨，采用随机双盲对照，入组患者既往治疗背景复杂，具有较好的代表性。核心发现是suvemcitug联合化疗相比单纯化疗，显著延长了中位PFS（5.5个月 vs 2.7个月）和OS（15.3个月 vs 14.0个月），且安全性可控，为这一难治性人群提供了新的有效治疗选择。其创新性在于验证了suvemcitug在这一特定人群中的确切获益，但摘要未提供不同化疗亚组的分析数据，也未详细报告生活质量等次要终点的具体结果，是其局限性。

---

## 11. 单细胞图谱揭示与多发性骨髓瘤预后相关的骨髓免疫微环境失调特征。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41514053)
**期刊：** Nature cancer
**PMID：** 41514053
**DOI：** 10.1038/s43018-025-01072-4

### 第一部分 原文与翻译

**英文原标题：** A single-cell atlas characterizes dysregulation of the bone marrow immune microenvironment associated with outcomes in multiple myeloma.

> **英文摘要：**
> Multiple myeloma (MM) remains incurable despite advances in treatment options. Although tumor subtypes and specific DNA abnormalities are linked to worse prognosis, the impact of immune dysfunction on disease emergence and/or treatment sensitivity remains unclear. We developed an Immune Atlas of MM by generating profiles of 1,397,272 single cells from the bone marrow (BM) of 337 newly diagnosed participants and characterized immune and hematopoietic cell populations. Cytogenetic risk-based analysis revealed heterogeneous associations with T cells of BM, with 17p13 deletion showing distinct enrichment of a type 1 interferon signature. The disease progression-based analysis revealed the presence of a proinflammatory immune senescence-associated secretory phenotype in rapidly progressing participants. Furthermore, signaling analyses suggested active intercellular communication involving a proliferation-inducing ligand and B cell maturation antigen, potentially promoting tumor growth and survival. Lastly, using independent discovery and validation cohorts, we demonstrated that integrating immune cell signatures with known tumor cytogenetics and individual characteristics significantly improves stratification for the prediction of survival.

> **中文摘要：**
> 尽管治疗手段不断进步，多发性骨髓瘤（MM）仍无法治愈。虽然肿瘤亚型和特定的DNA异常与较差的预后相关，但免疫功能障碍对疾病发生和/或治疗敏感性的影响仍不清楚。我们通过分析337名新诊断参与者骨髓中的1,397,272个单细胞图谱，构建了MM的免疫图谱，并对免疫和造血细胞群进行了表征。基于细胞遗传学风险的分析揭示了与骨髓T细胞的异质性关联，其中17p13缺失显示出独特的1型干扰素特征富集。基于疾病进展的分析揭示了在快速进展的参与者中存在一种促炎性的免疫衰老相关分泌表型。此外，信号传导分析表明，涉及增殖诱导配体和B细胞成熟抗原的活跃细胞间通讯可能促进了肿瘤的生长和存活。最后，利用独立的发现队列和验证队列，我们证明了将免疫细胞特征与已知的肿瘤细胞遗传学及个体特征相结合，能显著改善生存预测的分层能力。

### 第二部分 AI 大师评价

本研究旨在通过构建大规模单细胞图谱，系统解析多发性骨髓瘤（MM）骨髓免疫微环境的失调特征及其与预后的关联。其核心创新在于整合了337例新诊断患者的近140万个单细胞数据，从细胞遗传学风险、疾病进展速度及细胞间通讯等多个维度，揭示了特定的免疫失调模式（如1型干扰素特征、衰老相关分泌表型）与不良预后的关系。方法学上，研究结合了发现与验证队列，证实了整合免疫特征能显著提升生存预测的分层效能，为理解MM的免疫发病机制和开发新的治疗策略提供了重要依据。然而，研究主要基于新诊断患者，治疗过程中的免疫微环境动态变化及其对治疗反应的影响仍需进一步探索。

---

## 12. 病毒、小细胞外囊泡及其他纳米级生物颗粒的声学分离与纯化。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41514051)
**期刊：** Nature protocols
**PMID：** 41514051
**DOI：** 10.1038/s41596-025-01286-x

### 第一部分 原文与翻译

**英文原标题：** Acoustic separation and isolation of viruses, small extracellular vesicles and other nanoscale bioparticles.

> **英文摘要：**
> The isolation of small extracellular vesicles (sEVs), viruses and other nanoscale lipid particles from biofluids offers actionable possibilities for advancing disease diagnosis, drug delivery, regenerative medicine, personalized medicine and immunotherapy. Several methods are available to isolate sEVs from biofluids and acoustic techniques provide distinct advantages. Challenges constraining its wider application encompass the absence of adequate procedures for fabrication, implementation and performance validation. These issues impede the development of protocols applicable to nanoscale bioparticles experiencing acoustic isolation effects. Here we present a detailed protocol for acoustic separation of nanoscale bioparticles from biofluids, including plasma and saliva, achieving both high purity and throughput suitable for routine application. This protocol offers a comprehensive, step-by-step guide for the design and fabrication of the acoustic separation device, the establishment of the experimental setup and the isolation of bioparticles. To ensure reliability, rigor and reproducibility, we delineate essential procedures, including acoustic field optimization, channel fabrication and biofluid preparation, subsequently validating the protocol and its performance across different operators. Our protocol further encompasses procedures for data collection and analysis, which are essential for characterizing viruses and sEVs, as well as for evaluating their quality and integrity. This protocol enables researchers to perform high-quality isolation of nanoscale bioparticles, providing access to reliable acoustic separation techniques. Standardizing this technique will pave the way for discoveries in virology and intercellular communication research, with applications in medicine, biology, and materials science.

> **中文摘要：**
> 从生物体液中分离小细胞外囊泡（sEVs）、病毒及其他纳米级脂质颗粒，为推进疾病诊断、药物递送、再生医学、个性化医疗和免疫疗法提供了可行的可能性。现有多种方法可从生物体液中分离sEVs，其中声学技术具有独特优势。限制其更广泛应用的关键挑战在于缺乏足够的设备制造、操作实施和性能验证流程。这些问题阻碍了适用于经历声学分离效应的纳米级生物颗粒的标准化方案的开发。本文提出了一种从血浆和唾液等生物体液中声学分离纳米级生物颗粒的详细方案，该方案兼具高纯度和高通量，适合常规应用。本方案提供了关于声学分离装置的设计与制造、实验平台的建立以及生物颗粒分离的全面、分步指南。为确保可靠性、严谨性和可重复性，我们详细阐述了包括声场优化、通道制造和生物体液制备在内的关键步骤，并随后在不同操作者间验证了该方案及其性能。我们的方案还涵盖了数据收集与分析流程，这对于表征病毒和sEVs以及评估其质量和完整性至关重要。本方案使研究人员能够实现高质量的纳米级生物颗粒分离，从而获得可靠的声学分离技术。标准化该技术将为病毒学和细胞间通讯研究领域的发现铺平道路，并在医学、生物学和材料科学中得到应用。

### 第二部分 AI 大师评价

本研究旨在提供一种标准化、可重复的声学分离方案，用于从血浆和唾液等生物体液中高效、高纯度地分离病毒、小细胞外囊泡等纳米级生物颗粒。其核心创新在于详细阐述了从设备设计制造、声场优化到实验操作与性能验证的全流程标准化步骤，弥补了该技术在应用流程和验证方法上的空白，旨在推动其从实验室走向常规应用。该方案通过跨操作者验证强调了方法的可靠性与可重复性，并整合了后续数据分析指南，为下游应用奠定基础。然而，其局限性可能在于方案的实施对特定设备和技术平台存在依赖性，且未在更广泛的生物流体类型或更复杂的临床样本中进行充分验证，其长期稳定性和大规模应用的可行性仍有待进一步考察。

---

## 13. 用于探究ATAC组蛋白乙酰转移酶复合物的复合物特异性抑制剂。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41513852)
**期刊：** Nature chemical biology
**PMID：** 41513852
**DOI：** 10.1038/s41589-025-02132-7

### 第一部分 原文与翻译

**英文原标题：** Complex-specific inhibitors for interrogating ATAC histone acetyltransferase complex.

> **英文摘要：**
> Histone acetyltransferases (HATs) modify chromatin to regulate gene expression. Instead of acting alone, HATs function in complexes with other proteins, leading to variations in substrate specificity, genomic localization and cellular function. To understand the complex-dependent roles of HATs, we present a chemical approach to specifically dissociate ATAC (Ada-two-A-containing) HAT complex from chromatin without perturbing other complexes. Rather than targeting the shared HAT enzyme, we developed chemical inhibitors for an ATAC-specific subunit, YEATS2. The most effective inhibitor, LS-170, specifically reduced the chromatin occupancy of the ATAC complex, decreased the ATAC-dependent histone acetylation level and downregulated the expression of ATAC-governed genes, leading to significantly suppressed tumor growth in a lung cancer mouse model. This study not only sheds light on the regulatory roles of the ATAC HAT complex in gene转录 but also provides evidence that the chemical inhibition of the ATAC complex can be a promising therapeutic strategy.

> **中文摘要：**
> 组蛋白乙酰转移酶（HATs）通过修饰染色质来调控基因表达。HATs并非单独作用，而是与其他蛋白质形成复合物发挥功能，这导致了其底物特异性、基因组定位和细胞功能的差异。为了理解HATs依赖于复合物的功能，我们提出了一种化学方法，能够在不干扰其他复合物的情况下，特异性地将ATAC（含Ada-two-A）HAT复合物从染色质上解离。我们没有靶向共有的HAT酶，而是针对ATAC特异性亚基YEATS2开发了化学抑制剂。其中最有效的抑制剂LS-170，特异性地降低了ATAC复合物在染色质上的占有率，降低了ATAC依赖的组蛋白乙酰化水平，并下调了ATAC调控基因的表达，从而在肺癌小鼠模型中显著抑制了肿瘤生长。这项研究不仅阐明了ATAC HAT复合物在基因转录中的调控作用，还提供了证据表明化学抑制ATAC复合物可能是一种有前景的治疗策略。

### 第二部分 AI 大师评价

本研究旨在阐明HATs在特定复合物（ATAC）中的功能。其核心创新在于开发了一种针对复合物特异性亚基YEATS2的化学抑制剂LS-170，而非靶向共有的催化酶，从而实现了对ATAC复合物功能的精准干预。研究发现，LS-170能特异性破坏ATAC复合物的染色质定位及其下游的组蛋白乙酰化与基因表达，并在肺癌小鼠模型中展现出显著的抗肿瘤效果。这项工作不仅为理解HAT复合物的功能特异性提供了有力工具，也验证了靶向此类复合物作为癌症治疗新策略的可行性，但该策略在更广泛肿瘤类型中的疗效及潜在脱靶效应仍需进一步探索。

---

## 14. 撤稿声明：Claudin-1通过激活c-Abl-ERK信号通路诱导人肝细胞上皮-间质转化。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41513821)
**期刊：** Oncogene
**PMID：** 41513821
**DOI：** 10.1038/s41388-025-03673-w

### 第一部分 原文与翻译

**英文原标题：** Retraction Note: Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

该文献为一篇撤稿声明，其原研究旨在探讨紧密连接蛋白Claudin-1在人肝细胞中通过激活c-Abl-ERK信号通路诱导上皮-间质转化的分子机制。原研究可能采用了细胞模型与信号通路分析等方法，试图揭示Claudin-1在肝细胞生物学行为调控中的新功能。然而，作为撤稿说明，其核心信息在于该研究结论的可靠性已被撤回，这提示原研究可能存在数据真实性、可重复性或解释方面的重大缺陷，因此其创新性与发现的有效性已不再成立，强调了科研诚信与结果验证的重要性。

---

## 15. 一个含有SET结构域的蛋白与HCF-1共同维持跨代表观遗传记忆。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41513691)
**期刊：** Nature communications
**PMID：** 41513691
**DOI：** 10.1038/s41467-025-68200-7

### 第一部分 原文与翻译

**英文原标题：** A SET domain-containing protein and HCF-1 maintain transgenerational epigenetic memory.

> **英文摘要：**
> Transgenerational epigenetic inheritance (TEI) allows epigenetic information to pass across generations through mechanisms such as small RNAs and histone modifications. Histone methylation is often deposited by SET domain-containing methyltransferases. Some SET proteins lack catalytic activity but still regulate chromatin and gene expression. Here, we characterize SET-24, a catalytically inactive SET domain protein that localizes to germline nuclei and is essential for germline immortality in Caenorhabditis elegans. In set-24 mutants, small RNA-mediated epigenetic silencing is impaired. Proteomic, yeast two-hybrid, and pull-down assays show that SET-24 interacts with HCF-1, a chromatin factor linked to complexes like COMPASS, which deposits H3K4me3. Loss of SET-24 leads to increased H3K4me3 at transcription start sites of hundreds of genes. Although transcription remains largely unchanged, small RNA production is disrupted for about 30% of these genes. We propose that SET-24 preserves germline epigenetic memory by sustaining a chromatin environment that supports small RNA biogenesis across generations.

> **中文摘要：**
> 跨代表观遗传允许表观遗传信息通过小RNA和组蛋白修饰等机制在代际间传递。组蛋白甲基化通常由含有SET结构域的甲基转移酶催化沉积。一些SET蛋白缺乏催化活性，但仍能调控染色质和基因表达。本文中，我们表征了SET-24，这是一种定位于生殖系细胞核、对秀丽隐杆线虫生殖系永生性至关重要的无催化活性的SET结构域蛋白。在set-24突变体中，小RNA介导的表观遗传沉默受损。蛋白质组学、酵母双杂交和下拉实验表明，SET-24与HCF-1相互作用，后者是一种与沉积H3K4me3的COMPASS等复合物相关的染色质因子。SET-24的缺失导致数百个基因转录起始位点的H3K4me3水平升高。尽管转录基本保持不变，但其中约30%的基因的小RNA生成受到破坏。我们提出，SET-24通过维持一个支持小RNA跨代生物发生的染色质环境，来保护生殖系的表观遗传记忆。

### 第二部分 AI 大师评价

本研究旨在揭示无催化活性的SET结构域蛋白SET-24在维持跨代表观遗传记忆中的关键作用。通过在线虫模型中结合遗传学、蛋白质组学及生化方法，研究发现SET-24通过与染色质因子HCF-1互作，调控H3K4me3修饰水平，从而影响特定基因位点的小RNA生成，而不显著改变转录本身。其创新性在于发现了一种不依赖甲基转移酶活性的SET蛋白调控表观遗传记忆的新机制，为理解跨代遗传提供了新视角。局限性在于研究主要在线虫中进行，其机制在高等生物中的普适性有待验证，且SET-24/HCF-1复合物精确的分子作用模式仍需进一步阐明。

---

## 16. sCellST：基于H&E染色图像预测单细胞基因表达

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41513659)
**期刊：** Nature communications
**PMID：** 41513659
**DOI：** 10.1038/s41467-025-67965-1

### 第一部分 原文与翻译

**英文原标题：** sCellST predicts single-cell gene expression from H& E images.

> **英文摘要：**
> Understanding the spatial organization of individual cell types within tissue and how this organization is disrupted in disease, is a central question in biology and medicine. Hematoxylin and eosin-stained slides are widely available and provide detailed morphological context, while spatial gene expression profiling offers complementary molecular insights, though it remains costly and limited in accessibility. Predicting gene expression directly from histological images is therefore an attractive goal. However, existing approaches typically rely on small image patches, limiting resolution and the ability to capture fine-grained morphological variation. Here, we introduce a deep learning approach that predicts single-cell gene expression from morphology, matching patch-based methods on spot level prediction tasks. The model recovers biologically meaningful expression patterns across two cancer datasets and distinguishes fine cell populations. This approach enables molecular-level interpretation of standard histological slides at scale, offering new opportunities to study tissue organization and cellular diversity in health and disease.

> **中文摘要：**
> 理解组织中单个细胞类型的空间组织结构，以及这种结构在疾病中如何被破坏，是生物学和医学的核心问题。苏木精-伊红（H&E）染色切片广泛可得，并能提供详细的形态学背景信息，而空间基因表达谱分析则提供了互补的分子层面的见解，尽管其成本高昂且可及性有限。因此，直接从组织学图像预测基因表达是一个颇具吸引力的目标。然而，现有方法通常依赖于小的图像块，限制了分辨率以及捕捉细粒度形态学变化的能力。在此，我们介绍一种深度学习方法，该方法可从形态学预测单细胞基因表达，在点水平预测任务上与基于图像块的方法表现相当。该模型在两个癌症数据集中恢复了具有生物学意义的表达模式，并能区分精细的细胞群体。这种方法使得大规模地对标准组织学切片进行分子水平解读成为可能，为研究健康和疾病状态下的组织结构和细胞多样性提供了新的机遇。

### 第二部分 AI 大师评价

本研究旨在解决空间转录组学成本高、可及性有限的问题，提出了一种创新的深度学习模型sCellST，能够直接从广泛可得的H&E染色图像中预测单细胞水平的基因表达。其核心方法突破在于摆脱了传统小图像块的限制，实现了基于形态学的单细胞分辨率预测，在点水平任务上达到与现有方法相当的性能。研究发现，该模型能有效恢复癌症数据集中有生物学意义的表达模式并区分精细细胞亚群，创新性地将常规病理切片与分子信息大规模关联，为组织生物学研究提供了强大工具。其局限性在于，模型的预测能力高度依赖于训练数据的质量和覆盖度，且目前主要在癌症数据集中验证，在其他组织类型和疾病中的普适性有待进一步评估。

---

## 17. 一项针对男性慢性前列腺炎/慢性盆腔疼痛综合征的大规模多祖先全基因组关联研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41513650)
**期刊：** Nature communications
**PMID：** 41513650
**DOI：** 10.1038/s41467-025-64954-2

### 第一部分 原文与翻译

**英文原标题：** A large-scale multi-ancestry genome-wide association study of chronic prostatitis/chronic pelvic pain syndrome in men.

> **英文摘要：**
> Chronic prostatitis/chronic pelvic pain syndrome is common, and it impacts men's health and quality of life. The genetic basis of this condition remains largely unknown. Here, we conduct a GWAS using data from the Million Veteran Program of over 590,000 men of European, African, and Hispanic ancestry, including 14,575 chronic prostatitis/chronic pelvic pain syndrome cases. The multi-ancestry analysis identifies eight novel loci associated with chronic prostatitis/chronic pelvic pain syndrome risk, an increase from three significant genome-wide loci found in the European participants alone. We also estimate the genetic correlations between chronic prostatitis/chronic pelvic pain syndrome and 12 phenotypes. Notably, the genetic correlation between chronic prostatitis/chronic pelvic pain syndrome and prostate cancer is not significant. Further, Mendelian randomization shows a significant, potentially bidirectional causal relationship between chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia, but not between chronic prostatitis/chronic pelvic pain syndrome and prostate cancer, suggesting a complex interplay between chronic prostatitis/chronic pelvic pain syndrome and benign prostatic hyperplasia. Results of bivariate causal mixture modeling indicate that some of the same genetic variants likely contribute to the development of chronic prostatitis/chronic pelvic pain syndrome, benign prostatic hyperplasia, and prostate cancer.

> **中文摘要：**
> 慢性前列腺炎/慢性盆腔疼痛综合征是一种常见疾病，影响男性健康和生活质量。该疾病的遗传基础在很大程度上仍属未知。本研究利用来自“百万退伍军人计划”中超过59万名欧洲、非洲和西班牙裔男性（包括14,575例慢性前列腺炎/慢性盆腔疼痛综合征病例）的数据进行了全基因组关联研究。多祖先分析发现了八个与慢性前列腺炎/慢性盆腔疼痛综合征风险相关的新位点，相较于仅在欧洲参与者中发现的三个显著全基因组位点有所增加。我们还评估了慢性前列腺炎/慢性盆腔疼痛综合征与12种表型之间的遗传相关性。值得注意的是，慢性前列腺炎/慢性盆腔疼痛综合征与前列腺癌之间的遗传相关性并不显著。此外，孟德尔随机化分析显示，慢性前列腺炎/慢性盆腔疼痛综合征与良性前列腺增生之间存在显著且可能是双向的因果关系，但与前列腺癌之间则无此关系，这表明慢性前列腺炎/慢性盆腔疼痛综合征与良性前列腺增生之间存在复杂的相互作用。双变量因果混合模型的结果表明，一些相同的遗传变异可能同时参与了慢性前列腺炎/慢性盆腔疼痛综合征、良性前列腺增生和前列腺癌的发生发展。

### 第二部分 AI 大师评价

本研究旨在通过大规模多祖先全基因组关联研究，揭示慢性前列腺炎/慢性盆腔疼痛综合征的遗传基础。其核心创新在于利用“百万退伍军人计划”的多样化队列，将显著关联位点从仅欧洲人群的三个扩展到多祖先背景下的八个，显著提升了发现能力。研究发现该病与良性前列腺增生存在潜在双向因果关系，但与前列腺癌无显著遗传相关，这为理解其独特的病理生理机制提供了关键线索。然而，研究主要基于退伍军人队列，可能存在选择偏倚，且发现的位点需要进一步功能验证以明确其生物学机制。

---

## 18. 通过多组学网络分析鉴定ACBP为纤毛病相关肥胖的潜在治疗靶点

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41513648)
**期刊：** Nature communications
**PMID：** 41513648
**DOI：** 10.1038/s41467-025-66235-4

### 第一部分 原文与翻译

**英文原标题：** Identification of ACBP as a potential target in ciliopathic obesity through multi-omics network analysis.

> **英文摘要：**
> Ciliopathies are genetic disorders characterized by defective primary cilia function, with obesity as a clinical manifestation in certain cases, including Alström syndrome, which is caused by ALMS1 mutations. The link between cilia and lipid metabolism remains poorly understood, but evidence suggests a role for impaired autophagy. Autophagy affects both intra- and extracellular levels of ACBP, which can act as an obesogenic factor. Our multi-omics study reveals early hepatic dyslipidemia, impaired autophagy, and hepatic accumulation of ACBP in presymptomatic male mice lacking Alms1 gene. These conditions are consistent with the obesogenic phenotype and with alterations in the gut microbiota that manifest as the mice age and develop obesity. Importantly, reducing excessive ACBP with a neutralizing monoclonal antibody limits weight gain and metabolic defects in Alms1 mice in an autophagy-independent manner. Altogether, the data support the idea that ciliopathy-associated obesity, particularly Alström syndrome, may be mitigated by ACBP neutralization.

> **中文摘要：**
> 纤毛病是以原发性纤毛功能缺陷为特征的遗传性疾病，在某些病例中肥胖是其临床表现之一，包括由ALMS1突变引起的阿尔斯特伦综合征。纤毛与脂质代谢之间的联系仍知之甚少，但有证据表明自噬受损在其中发挥作用。自噬影响ACBP的细胞内和细胞外水平，而ACBP可作为一种致肥胖因子。我们的多组学研究揭示了在缺乏Alms1基因的、处于症状前期的雄性小鼠中，存在早期肝脏脂质代谢紊乱、自噬受损以及ACBP在肝脏的积累。这些状况与致肥胖表型以及随着小鼠年龄增长和肥胖发生而显现的肠道微生物群改变相一致。重要的是，使用中和性单克隆抗体减少过量的ACBP，能以不依赖于自噬的方式限制Alms1小鼠的体重增加和代谢缺陷。总之，这些数据支持了以下观点：纤毛病相关肥胖，特别是阿尔斯特伦综合征，可能通过ACBP中和得到缓解。

### 第二部分 AI 大师评价

本研究旨在阐明纤毛病相关肥胖的分子机制并探索潜在治疗靶点。研究团队运用多组学网络分析方法，在Alms1缺陷小鼠模型中，系统揭示了自噬受损、ACBP积累与肥胖表型及肠道菌群改变的关联。其核心创新性发现是，通过中和抗体靶向ACBP可有效改善代谢异常，且该作用不依赖于自噬通路，为阿尔斯特伦综合征等纤毛病提供了新的治疗思路。然而，研究主要基于雄性小鼠模型，且ACBP中和疗法的长期安全性与在人体中的有效性仍需进一步验证。

---

## 19. XRCC4的O-GlcNAc糖基化调控其稳定性并赋予癌细胞对DNA双链断裂损伤的抗性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41513635)
**期刊：** Cell death & disease
**PMID：** 41513635
**DOI：** 10.1038/s41419-025-08209-4

### 第一部分 原文与翻译

**英文原标题：** O-GlcNAcylation of XRCC4 controls its stability and confers resistance to DNA double-strand break damage in cancer cells.

> **英文摘要：**
> X-ray repair cross-complementing protein 4 (XRCC4), a non-homologous end-joining protein involved in DNA double-strand break repair, is highly expressed in human cancer cells and tissues. A prior OGT interactome study identified XRCC4 as a candidate for O-GlcNAcylation. O-GlcNAcylation levels, a post-translational modification found on nuclear and cytosolic proteins, are also elevated in various cancers. However, the direct regulatory mechanism linking O-GlcNAcylation to XRCC4 function in cancer cells remains unclear. Here, we found that XRCC4 is O-GlcNAcylated at threonine 308, enhancing its stability by inhibiting TRIM21-mediated ubiquitin-dependent proteasomal degradation. O-GlcNAcylation elevated XRCC4 protein levels during DNA double-strand break damage, thereby conferring resistance to such damage. Additionally, XRCC4 Thr308 O-GlcNAcylation promotes cancer proliferation, invasion, and in vivo tumor growth. These findings suggest that downregulating O-GlcNAcylation on XRCC4 could be a potential therapeutic strategy to increase cancer sensitivity to chemotherapy or radiotherapy.

> **中文摘要：**
> X射线修复交叉互补蛋白4（XRCC4）是一种参与DNA双链断裂修复的非同源末端连接蛋白，在人类癌细胞和组织中高表达。一项先前的OGT互作组研究将XRCC4鉴定为O-GlcNAc糖基化的候选底物。O-GlcNAc糖基化是一种存在于核蛋白和胞质蛋白的翻译后修饰，其水平在多种癌症中也升高。然而，在癌细胞中，将O-GlcNAc糖基化与XRCC4功能联系起来的直接调控机制仍不清楚。本研究中，我们发现XRCC4在苏氨酸308位点发生O-GlcNAc糖基化，通过抑制TRIM21介导的泛素依赖性蛋白酶体降解来增强其稳定性。O-GlcNAc糖基化在DNA双链断裂损伤期间提升了XRCC4蛋白水平，从而赋予细胞对此类损伤的抗性。此外，XRCC4 Thr308位点的O-GlcNAc糖基化促进了癌细胞的增殖、侵袭和体内肿瘤生长。这些发现表明，下调XRCC4的O-GlcNAc糖基化可能是一种潜在的治疗策略，可提高癌症对化疗或放疗的敏感性。

### 第二部分 AI 大师评价

本研究旨在阐明O-GlcNAc糖基化调控DNA修复蛋白XRCC4在癌细胞中功能的具体分子机制。研究通过鉴定XRCC4在Thr308位点的特异性O-GlcNAc修饰，揭示了该修饰通过拮抗TRIM21介导的泛素化降解来稳定XRCC4蛋白，从而增强癌细胞对DNA双链断裂损伤的抵抗能力，并促进其恶性表型。其创新性在于首次建立了O-GlcNAc修饰、XRCC4蛋白稳定性与癌细胞DNA损伤耐受性之间的直接因果联系，并提出了靶向该修饰以增敏放化疗的潜在新策略。然而，研究主要基于体外和动物模型，其临床转化价值及在特定癌症类型中的普适性仍需进一步验证。

---

## 20. ZC3H15通过募集TRIM56调控PTEN泛素化并促进非小细胞肺癌恶性进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41513632)
**期刊：** Cell death & disease
**PMID：** 41513632
**DOI：** 10.1038/s41419-025-08138-2

### 第一部分 原文与翻译

**英文原标题：** ZC3H15 regulates the ubiquitination of PTEN via recruitment of TRIM56 and promotes malignant progression of non-small cell lung cancer.

> **英文摘要：**
> Lung cancer is one of the most common cancers worldwide and the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC) accounts for 85% of lung cancer cases and has a 5-year survival rate of ~19%. Since more than half of NSCLC patients present with metastatic disease at the time of diagnosis, early diagnosis is crucial for providing patients with the most effective treatment strategy. This study integrated transcriptome data between cancer and adjacent tissues from GEO and TCGA databases through bioinformatics analysis, and screened zinc finger CCCH-type containing 15 (ZC3H15) as a key differentially expressed gene in NSCLC. ZC3H15 expression levels were found to be significantly higher in NSCLC tissue than normal tissue and correlated with tumor size, TNM stage, lymph node metastasis and poor prognosis of patients. Overexpression of ZC3H15 promoted the proliferation, migration and invasion of NSCLC cells through activation of the AKT-mTOR signaling pathway. To elucidate the underlying molecular mechanism, we determined that ZC3H15 could bind to PTEN through its DFRP structural domain and recruited the E3 ligase TRIM56 to promote PTEN ubiquitination. In addition, overexpression of ZC3H15 increased the resistance of NSCLC cells to cisplatin. Therefore, ZC3H15 promotes the malignant phenotype of NSCLC through recruitment of TRIM56 to ubiquitinate PTEN, decreasing its expression and driving increased AKT-mTOR signaling pathway and cisplatin resistance. These findings provide a scientific basis for the development of targeted therapies against ZC3H15, which may lead to new therapeutic strategies for NSCLC patients.

> **中文摘要：**
> 肺癌是全球最常见的癌症之一，也是癌症相关死亡的主要原因。非小细胞肺癌（NSCLC）占肺癌病例的85%，其5年生存率约为19%。由于超过一半的NSCLC患者在诊断时已出现转移性疾病，早期诊断对于为患者提供最有效的治疗策略至关重要。本研究通过生物信息学分析整合了来自GEO和TCGA数据库的癌组织与癌旁组织的转录组数据，筛选出含锌指CCCH型结构15（ZC3H15）作为NSCLC中的关键差异表达基因。研究发现，ZC3H15在NSCLC组织中的表达水平显著高于正常组织，并且与肿瘤大小、TNM分期、淋巴结转移及患者不良预后相关。过表达ZC3H15通过激活AKT-mTOR信号通路促进了NSCLC细胞的增殖、迁移和侵袭。为了阐明其潜在的分子机制，我们确定ZC3H15可以通过其DFRP结构域与PTEN结合，并募集E3连接酶TRIM56以促进PTEN泛素化。此外，过表达ZC3H15增加了NSCLC细胞对顺铂的耐药性。因此，ZC3H15通过募集TRIM56泛素化PTEN，降低其表达，并驱动AKT-mTOR信号通路增强和顺铂耐药，从而促进NSCLC的恶性表型。这些发现为开发针对ZC3H15的靶向疗法提供了科学依据，可能为NSCLC患者带来新的治疗策略。

### 第二部分 AI 大师评价

本研究旨在探索ZC3H15在非小细胞肺癌（NSCLC）恶性进展中的功能与机制。通过整合GEO和TCGA数据库的转录组数据筛选出ZC3H15，并利用细胞功能实验和分子机制研究，揭示了ZC3H15通过其DFRP结构域结合PTEN并募集E3连接酶TRIM56，介导PTEN泛素化降解，进而激活AKT-mTOR通路并诱导顺铂耐药。其创新性在于首次阐明了ZC3H15-TRIM56-PTEN这一新的调控轴，为NSCLC提供了潜在的治疗靶点。然而，研究主要基于生物信息学分析和体外实验，缺乏体内模型（如动物实验）的验证，且ZC3H15作为治疗靶点的成药性及临床转化潜力仍需进一步探索。

---

## 21. 基于一线免疫化疗的滤泡性淋巴瘤患者无事件生存期全基因组关联研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41513626)
**期刊：** Blood cancer journal
**PMID：** 41513626
**DOI：** 10.1038/s41408-025-01435-1

### 第一部分 原文与翻译

**英文原标题：** Genome-wide association study of event-free survival in follicular lymphoma patients treated with front-line immunochemotherapy.

> **英文摘要：**
> Genome-wide association studies (GWAS) have identified germline genetic variants for follicular lymphoma (FL) susceptibility. We conducted a GWAS of prognosis in FL patients to identify genetic predictors of event-free survival (EFS) as well as failure within the first 24 months after treatment initiation (EFS24) using patients treated with rituximab-based immunochemotherapy from three clinical trials and one prospective observational study (N = 1054). Statistical approaches consisted of a pooled GWAS of the four cohorts and a leave-one-cohort-out (LOCO) strategy to identify robust findings that replicated across the four cohorts. The top SNPs for EFS and EFS24 were marked by rs72625024 at 3q27.3 near FETUB and HRG (P = 9.37 × 10) and rs114695031 at 14q32.13 near TCL6 (P = 1.93 × 10), respectively. These two loci, which were discovered and validated in all 4 LOCO rounds, map near long-non-coding RNAs with putative tumor suppressor functions. Our results pinpoint potential novel biology and the contribution of host genetics to prognosis in FL.

> **中文摘要：**
> 全基因组关联研究（GWAS）已鉴定出与滤泡性淋巴瘤（FL）易感性相关的种系遗传变异。我们对接受基于利妥昔单抗的免疫化疗的FL患者（来自三项临床试验和一项前瞻性观察性研究，N=1054）进行了一项预后GWAS，旨在识别无事件生存期（EFS）以及治疗开始后24个月内失败（EFS24）的遗传预测因子。统计方法包括对四个队列的合并GWAS以及留一队列交叉验证（LOCO）策略，以识别在四个队列中均能复现的稳健发现。与EFS和EFS24最相关的SNP分别是位于3q27.3靠近FETUB和HRG基因的rs72625024（P=9.37×10）以及位于14q32.13靠近TCL6基因的rs114695031（P=1.93×10）。这两个在所有4轮LOCO验证中均被发现和验证的位点，定位在具有推定肿瘤抑制功能的长链非编码RNA附近。我们的结果揭示了FL中潜在的新生物学机制以及宿主遗传对预后的贡献。

### 第二部分 AI 大师评价

本研究旨在通过GWAS探索宿主遗传因素对接受一线免疫化疗的滤泡性淋巴瘤患者预后的影响。其方法学严谨，整合了多个临床试验和观察性研究数据，并采用留一队列交叉验证策略以增强结果的稳健性和可重复性。核心发现是鉴定出两个与无事件生存期及早期治疗失败显著相关的全新遗传位点，且它们邻近具有潜在抑癌功能的长链非编码RNA，这为理解FL的预后生物学机制提供了新视角。然而，研究结论主要基于遗传关联分析，其功能机制和临床转化价值仍需后续实验和独立队列验证。

---

## 22. HPV18位点特异性整合通过代谢重编程诱导的SpHK1/S1P/S1PR1通路功能障碍促进宫颈癌发生。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41513624)
**期刊：** Cell death & disease
**PMID：** 41513624
**DOI：** 10.1038/s41419-025-08195-7

### 第一部分 原文与翻译

**英文原标题：** Site-specific HPV18 integration facilitates cervical carcinogenesis through metabolic reprogramming-induced dysfunction of the SpHK1/S1P/S1PR1 pathway.

> **英文摘要：**
> Integration of high-risk human papillomavirus into specific loci of the genome is a pivotal event in cervical carcinogenesis; however, it's underlying mechanism remains largely undefined. Here, through establishing an 8q24 site-specific HPV18 gene knock-in cell model by utilizing the CRISPR/Cas9 system, we discover that HPV18 knock-in (HPV-KI) results in a global alteration of the genome's topologically associating domain structure and an up-regulation of cancer-related genes in HPV HaCaT cells, among which the significantly up-regulated IL-17 signaling pathway and S100A8/A9 are partitularly prominent. Further mechanistic study demonstrate that HPV-KI reprograms metabolic pathway, especially up-regulates glycolysis and subsequently facilitates glycerolipid synthesis in HaCaT cell, leading to sphingosine-1-phospate (S1P) secretion and enhanced SpHK1/S1P/S1PR1 signaling pathway, thereby activating the the MAPK and NF-κB signaling pathways followed by inducing the expression of S100A8/A9, and hence induces the malignant transformation of cells. Importantly, inhibition of the S1P/S1PR1 signaling pathway down-regulates the expression of S100A8/A9 and suppresses the growth of HPV-KI cells and xenograft derived from cervical cancer patient. These findings provide novel insights into HPV integration-induced cervical carcinogenesis and identify potential therapeutic targets for its treatment.

> **中文摘要：**
> 高危型人乳头瘤病毒整合到基因组的特定位点是宫颈癌发生的关键事件；然而，其潜在机制在很大程度上仍未明确。本研究通过利用CRISPR/Cas9系统建立8q24位点特异性HPV18基因敲入细胞模型，发现HPV18敲入导致HPV HaCaT细胞中基因组拓扑关联域结构的全局性改变以及癌症相关基因的上调，其中显著上调的IL-17信号通路和S100A8/A9尤为突出。进一步的机制研究表明，HPV-KI重编程了代谢通路，特别是上调了糖酵解并随后促进了HaCaT细胞中的甘油脂合成，导致1-磷酸鞘氨醇分泌和SpHK1/S1P/S1PR1信号通路增强，从而激活MAPK和NF-κB信号通路，进而诱导S100A8/A9的表达，并因此诱导细胞的恶性转化。重要的是，抑制S1P/S1PR1信号通路可下调S100A8/A9的表达，并抑制HPV-KI细胞和源自宫颈癌患者的异种移植瘤的生长。这些发现为HPV整合诱导的宫颈癌发生提供了新的见解，并确定了潜在的治疗靶点。

### 第二部分 AI 大师评价

本研究旨在阐明高危HPV基因组整合促进宫颈癌发生的具体分子机制。通过构建位点特异性HPV18敲入细胞模型，研究者创新性地将病毒整合事件与基因组三维结构改变、代谢重编程及特定信号通路激活联系起来，揭示了从HPV整合到S100A8/A9表达上调并驱动细胞恶性转化的完整通路（HPV整合→代谢重编程→SpHK1/S1P/S1PR1通路激活→MAPK/NF-κB激活→S100A8/A9表达→癌变）。其核心创新在于首次系统解析了HPV整合如何通过代谢重塑触发下游致癌信号，并验证了S1P/S1PR1通路作为潜在治疗靶点的价值。然而，研究主要基于细胞模型和部分体内实验，其在更复杂的人体微环境及临床样本中的普适性仍需进一步验证。

---

## 23. ATGL通过调控CEBPα/SCD1轴抑制急性髓系白血病细胞的铁死亡并诱导吉列替尼耐药

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41513623)
**期刊：** Cell death & disease
**PMID：** 41513623
**DOI：** 10.1038/s41419-025-08388-0

### 第一部分 原文与翻译

**英文原标题：** ATGL suppresses ferroptosis in acute myeloid leukemia cells by modulating the CEBPα/SCD1 axis and induces gilteritinib resistance.

> **英文摘要：**
> Metabolic reprogramming disrupts energy homeostasis and promotes tumor cell proliferation. In the present study, high expression of adipose triglyceride lipase (ATGL) in patients with acute myeloid leukemia (AML) predicted a poor clinical prognosis. Furthermore, the aberrant upregulation of ATGL was confirmed to promote the malignant progression of AML through gene ablation, overexpression, and pharmacological inhibition of ATGL, particularly in FLT3-ITD-mutated AML. RNA sequencing, lipid peroxidation, cellular iron, and ROS assays were performed to confirm the association of ATGL with ferroptosis. Mechanistically, ATGL is positively correlated with stearoyl-CoA decarboxylase 1 (SCD1) and promotes the malignant progression of AML by inhibiting ferroptosis through the CEBPα/SCD1 axis. We established gilteritinib-resistant MOLM-13 and MV4-11 cell lines and collected cells from patients with FLT3-ITD mutations to confirm that ATGL inhibitors increased the efficacy of gilteritinib. Consequently, we constructed an AML xenograft model using cells derived from patients with FLT3-ITD-mutated AML to confirm the efficacy of combining ATGL inhibitors with gilteritinib in vivo. This study provides novel therapeutic targets and monitoring indicators for AML, along with new treatment strategies for patients with FLT3-ITD-mutated AML and those with relapsed/refractory FLT3-ITD-mutated AML.

> **中文摘要：**
> 代谢重编程破坏能量稳态并促进肿瘤细胞增殖。在本研究中，急性髓系白血病（AML）患者中脂肪甘油三酯脂肪酶（ATGL）的高表达预示着不良的临床预后。此外，通过基因敲除、过表达和药物抑制ATGL，证实了ATGL的异常上调可促进AML的恶性进展，尤其是在FLT3-ITD突变的AML中。通过RNA测序、脂质过氧化、细胞铁和ROS检测，证实了ATGL与铁死亡的相关性。机制上，ATGL与硬脂酰辅酶A去饱和酶1（SCD1）呈正相关，并通过CEBPα/SCD1轴抑制铁死亡，从而促进AML的恶性进展。我们建立了吉列替尼耐药的MOLM-13和MV4-11细胞系，并收集了FLT3-ITD突变患者的细胞，证实ATGL抑制剂可增强吉列替尼的疗效。因此，我们利用FLT3-ITD突变AML患者的细胞构建了AML异种移植模型，以在体内验证ATGL抑制剂与吉列替尼联合使用的疗效。本研究为AML提供了新的治疗靶点和监测指标，并为FLT3-ITD突变AML患者以及复发/难治性FLT3-ITD突变AML患者提供了新的治疗策略。

### 第二部分 AI 大师评价

本研究旨在阐明ATGL在AML，特别是FLT3-ITD突变亚型中的促癌作用及机制。通过多层次的实验（基因操作、表型检测、耐药模型构建及体内验证），研究揭示了ATGL通过激活CEBPα/SCD1轴抑制铁死亡，从而驱动AML进展并诱导对靶向药吉列替尼的耐药。其创新性在于将脂代谢酶ATGL与铁死亡及靶向治疗耐药联系起来，并提出了联合抑制ATGL以克服耐药的新策略，为临床治疗提供了潜在新靶点。局限性在于，研究主要基于细胞系和动物模型，其临床转化效果及在更广泛AML亚型中的普适性仍需进一步验证。

---

## 24. N4BP1通过同时调控癌细胞与免疫微环境对口腔癌的发生至关重要。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41513619)
**期刊：** Cell death & disease
**PMID：** 41513619
**DOI：** 10.1038/s41419-025-08229-0

### 第一部分 原文与翻译

**英文原标题：** N4BP1 is essential for the development of oral cancer via controlling both cancer cells and immune microenvironment.

> **英文摘要：**
> N4BP1 specifically degrades a subset of mRNA targets through their coding sequences and functions as a negative regulator of inflammation; however, its role in cancer development remains undefined. N4BP1 exhibits the highest expression in head and neck squamous cell carcinoma among all analyzed cancer types. Unlike wild-type mice, N4bp1 mice did not develop visible tongue tumor masses in a 4-NQO-induced oral carcinogenesis model. Furthermore, N4bp1 mice (86% vs 0%) exhibited significantly prolonged survival compared to wild-type mice within 26 weeks in 4-NQO-induced oral carcinogenesis model. Single-cell profiling demonstrated that N4BP1-deficient epithelial cells arrest at an early stage of cancerous transformation, while wild-type epithelial cells efficiently progress to an advanced stage of cancer. In established human cancer cell lines, N4BP1 also plays a crucial role in proliferation, migration, colony formation, and in vivo growth. Transcriptome profiling identified CCL2 and GM-CSF as downstream targets of N4BP1 in oral cancer. Apart from its intrinsic role in cancer cells, N4BP1-deficient cancer cells induce the differentiation of macrophages into the M1 phenotype. In N4BP1-deficient tissues, CCL2 and GM-CSF were significantly increased, accompanied by the accumulation of M1 macrophages and neutrophils. Our results demonstrate that N4BP1 is an essential gene in tongue cancer development. N4BP1 not only drives cancer cell evolution but also establishes an immune-suppressive microenvironment. N4BP1 is an endoribonuclease that specifically regulates a subset of mRNA targets (including CCL2 and GM-CSF) and plays an essential role in oral cancer.

> **中文摘要：**
> N4BP1通过其编码序列特异性降解一部分mRNA靶标，并作为炎症的负向调节因子发挥作用；然而，其在癌症发展中的作用仍不明确。在所有分析的癌症类型中，N4BP1在头颈部鳞状细胞癌中表达最高。与野生型小鼠不同，在4-NQO诱导的口腔癌发生模型中，N4bp1小鼠未形成可见的舌部肿瘤团块。此外，在4-NQO诱导的口腔癌发生模型中，26周内N4bp1小鼠（86% vs 0%）的生存期较野生型小鼠显著延长。单细胞图谱分析表明，N4BP1缺陷的上皮细胞停滞在癌变的早期阶段，而野生型上皮细胞则能有效地进展到癌症晚期阶段。在已建立的人类癌细胞系中，N4BP1在增殖、迁移、集落形成和体内生长中也起着关键作用。转录组分析确定CCL2和GM-CSF是N4BP1在口腔癌中的下游靶点。除了其在癌细胞中的内在作用外，N4BP1缺陷的癌细胞还能诱导巨噬细胞向M1表型分化。在N4BP1缺陷的组织中，CCL2和GM-CSF显著增加，并伴有M1巨噬细胞和中性粒细胞的积聚。我们的结果表明，N4BP1是舌癌发生过程中的一个必需基因。N4BP1不仅驱动癌细胞演化，还建立了免疫抑制微环境。N4BP1是一种核糖核酸内切酶，特异性调控一部分mRNA靶标（包括CCL2和GM-CSF），并在口腔癌中发挥重要作用。

### 第二部分 AI 大师评价

本研究旨在阐明核糖核酸内切酶N4BP1在口腔癌发生中的关键作用及其机制。研究采用4-NQO诱导的小鼠口腔癌模型、单细胞测序、体外细胞功能实验及转录组分析等方法，系统揭示了N4BP1的双重功能。核心发现是N4BP1通过降解CCL2和GM-CSF等mRNA，不仅内在性地驱动癌细胞恶性进展，还通过抑制M1型巨噬细胞分化来塑造免疫抑制微环境，从而对口腔癌的发生至关重要。其创新性在于将N4BP1的分子功能与肿瘤细胞内在特性和免疫微环境调控有机联系起来，为靶向治疗提供了新思路；局限性在于研究主要基于小鼠模型和细胞系，其结论在人类患者中的普适性及具体的信号通路细节有待进一步临床前和临床研究验证。

---

## 25. VIRMA/IGF2BP3介导的ANLN上调通过与RhoA/YAP1/TEAD1信号通路形成正反馈环促进肝内胆管癌生长。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41513610)
**期刊：** Cell death & disease
**PMID：** 41513610
**DOI：** 10.1038/s41419-025-08197-5

### 第一部分 原文与翻译

**英文原标题：** VIRMA/IGF2BP3-mediated ANLN upregulation promotes intrahepatic cholangiocarcinoma growth by forming a positive feedback loop with RhoA/YAP1/TEAD1 signaling pathway.

> **英文摘要：**
> The prognosis of patients with intrahepatic cholangiocarcinoma (ICC) remains poor owing to the lack of effective targeted therapeutic strategies. Thus, the exploration of the molecular pathogenesis of ICC is urgently required. The cytoskeleton protein, anillin (ANLN), has been reported to contribute to various tumor growth by participating in cytokinesis via RhoA signaling. However, the exact physiological role and potential regulatory mechanism of ANLN in ICC are still not well understood. Based on spindle-related genes, integrated bioinformatic analyses identified ANLN as a potential candidate target for ICC. ANLN was elevated in ICC and predicted worse survival. Mechanistically, VIRMA-mediated m6A modification and IGF2BP3-dependent interaction collectively accounted for the upregulation of ANLN by maintaining its mRNA stability. Furthermore, the combination of ANLN and VIRMA or IGF2BP3 offered a greater predictive value than each marker alone in a large ICC cohort. Functional studies indicated that ANLN was involved in cancer cell proliferation and cell cycle. ANLN knockdown induced cytokinesis failure, DNA damage, and apoptosis in ICC cells. In addition to discovering the crucial role of ANLN in cytokinesis via RhoA activation, we also illustrated that ANLN restrained the Hippo pathway by enhancing the activity of RhoA signaling, which together contributed to ANLN-mediated tumor-promoting effects on ICC. Furthermore, YAP1-TEAD1 transcriptionally activated ANLN, subsequently establishing a self-reinforcing loop between ANLN and Hippo pathway, which was mediated by RhoA signaling as an intermediate regulatory node. Importantly, two clinical drugs, the RhoA inhibitor simvastatin and the YAP1/TEAD inhibitor verteporfin were determined to be the disruptors of this feed-forward signaling axis, inhibiting ICC tumor growth. These findings reveal the vital function of ANLN in ICC growth and provide promising treatment strategies for ICC.

> **中文摘要：**
> 由于缺乏有效的靶向治疗策略，肝内胆管癌（ICC）患者的预后仍然较差。因此，迫切需要探索ICC的分子发病机制。据报道，细胞骨架蛋白anillin（ANLN）通过RhoA信号参与胞质分裂，从而促进多种肿瘤的生长。然而，ANLN在ICC中的确切生理作用和潜在调控机制仍不清楚。基于纺锤体相关基因，综合生物信息学分析确定ANLN是ICC的潜在候选靶点。ANLN在ICC中表达升高，并预示着更差的生存率。从机制上讲，VIRMA介导的m6A修饰和IGF2BP3依赖性相互作用共同通过维持ANLN mRNA的稳定性来解释其上调。此外，在一个大型ICC队列中，ANLN与VIRMA或IGF2BP3的组合比单独使用任一标志物具有更大的预测价值。功能研究表明，ANLN参与癌细胞增殖和细胞周期。敲低ANLN会诱导ICC细胞发生胞质分裂失败、DNA损伤和凋亡。除了发现ANLN通过激活RhoA在胞质分裂中的关键作用外，我们还阐明ANLN通过增强RhoA信号活性来抑制Hippo通路，这两者共同促成了ANLN介导的对ICC的促肿瘤作用。此外，YAP1-TEAD1转录激活ANLN，随后在ANLN和Hippo通路之间建立了一个自我强化的环路，该环路以RhoA信号作为中间调控节点。重要的是，两种临床药物——RhoA抑制剂辛伐他汀和YAP1/TEAD抑制剂维替泊芬——被确定为该前馈信号轴的破坏剂，能够抑制ICC肿瘤生长。这些发现揭示了ANLN在ICC生长中的关键功能，并为ICC提供了有前景的治疗策略。

### 第二部分 AI 大师评价

本研究旨在探索肝内胆管癌（ICC）中ANLN的调控机制及其促癌功能。研究综合运用生物信息学筛选、临床队列验证、分子机制探索（m6A修饰、转录调控）和功能实验，揭示了VIRMA/IGF2BP3通过m6A修饰稳定ANLN mRNA上调其表达，而ANLN通过激活RhoA信号抑制Hippo通路并促进胞质分裂，同时YAP1/TEAD1又能转录激活ANLN，形成RhoA介导的正反馈环路。创新性在于系统解析了ANLN在ICC中的上游表观转录调控和下游信号网络，并验证了辛伐他汀和维替泊芬对该信号轴的靶向潜力，为ICC治疗提供了新思路。局限性在于研究主要在细胞和临床样本层面进行，缺乏体内动物模型对药物疗效和环路机制的进一步验证，且该正反馈环路的普适性及其与其他信号通路的交互作用有待阐明。

---

## 26. 通过空间转录组测序揭示血管免疫母细胞性T细胞淋巴瘤的肿瘤微环境异质性及其预后价值

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41513609)
**期刊：** Cell death & disease
**PMID：** 41513609
**DOI：** 10.1038/s41419-025-08212-9

### 第一部分 原文与翻译

**英文原标题：** Revealing tumor microenvironmental heterogeneity and prognostic value in angioimmunoblastic T-cell lymphoma via spatial transcriptome sequencing.

> **英文摘要：**
> Angioimmunoblastic T-cell lymphoma (AITL) represents the second most prevalent subtype of peripheral T-cell lymphoma, characterized by a dismal prognosis. However, a systematic exploration of tumor microenvironment (TME) features and their prognostic significance in AITL remains notably deficient. To address this knowledge gap, we conducted spatial transcriptome sequencing (ST-SEQ) and whole-exome sequencing in four AITLs and two noncancerous lymph nodes for discovery purposes, complemented by immunohistochemistry analyses on 37 AITL cases for validation. We identified 14 ST clusters, including five neoplastic clusters, wherein a global shift in B-cell phenotypes and enrichment of myeloid cells were observed. These findings underscore a hallmark of exacerbated inflammation and immune dysregulation within the neoplastic TME. Among the 4 ST-sequenced AITLs, 3 expressed high CD40-CD40LG activity, accompanied by the upregulation of immune-suppressive-associated genes, such as CCL17 and PDCD1. Conversely, the remaining patient displayed an uncommon absence of CD40-CD40LG activity but harbored a phagocytosis-associated tumor-associated macrophage (TAM)-enriched TME, which correlated with significantly reduced relapse rates and longer event-free survival (EFS), highlighting the critical value of precise TME stratification in tailoring AITL therapeutic strategies. Finally, trajectory analysis unveiled a distinct trajectory of molecular evolution within this TME landscape. Collectively, our findings illuminate the heterogeneity and prognostic implications of the TME in AITL, providing a robust foundation for the rational design of targeted immunotherapeutic approaches. These insights may substantially advance the development of personalized treatment strategies for AITL patients.

> **中文摘要：**
> 血管免疫母细胞性T细胞淋巴瘤（AITL）是外周T细胞淋巴瘤中第二常见的亚型，预后极差。然而，对AITL中肿瘤微环境（TME）特征及其预后意义的系统性探索仍明显不足。为填补这一知识空白，我们对4例AITL和2例非癌性淋巴结进行了空间转录组测序（ST-SEQ）和全外显子组测序以进行探索性研究，并辅以对37例AITL病例的免疫组织化学分析进行验证。我们鉴定出14个ST簇，其中包括5个肿瘤性簇，在其中观察到B细胞表型的整体转变和髓系细胞的富集。这些发现强调了肿瘤性TME内炎症加剧和免疫失调的标志性特征。在4例进行ST测序的AITL中，有3例表现出高CD40-CD40LG活性，并伴有免疫抑制相关基因（如CCL17和PDCD1）的上调。相反，剩余1例患者表现出罕见的CD40-CD40LG活性缺失，但其TME富含与吞噬作用相关的肿瘤相关巨噬细胞（TAM），这与显著降低的复发率和更长的无事件生存期（EFS）相关，突显了精确的TME分层在制定AITL治疗策略中的关键价值。最后，轨迹分析揭示了该TME景观内独特的分子进化轨迹。总之，我们的研究结果阐明了AITL中TME的异质性及其预后意义，为合理设计靶向免疫治疗方法奠定了坚实基础。这些见解可能极大地推动AITL患者个性化治疗策略的发展。

### 第二部分 AI 大师评价

本研究旨在系统揭示AITL肿瘤微环境（TME）的异质性及其预后价值。研究者创新性地结合空间转录组测序、全外显子组测序及大样本免疫组化验证，不仅识别出多个TME功能簇，还发现了CD40-CD40LG活性高低与TAM富集程度不同的两种预后相关亚型，为精准分层治疗提供了关键依据。其核心创新在于利用空间组学技术解析了AITL TME的细胞与分子空间分布及演化轨迹，将异质性特征与临床结局直接关联。然而，研究样本量有限，尤其是探索队列仅4例，其发现的普适性需在更大规模队列中进一步验证。

---

## 27. PRMT5通过组蛋白甲基化上调KCNMB4表达以促进晚期鼻咽癌的紫杉醇耐药性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41513606)
**期刊：** Cell death & disease
**PMID：** 41513606
**DOI：** 10.1038/s41419-025-08190-y

### 第一部分 原文与翻译

**英文原标题：** PRMT5 upregulates KCNMB4 expression via histone methylation to promote paclitaxel resistance in advanced nasopharyngeal carcinoma.

> **英文摘要：**
> Concurrent chemotherapy is the standard treatment strategy for advanced-stage nasopharyngeal carcinoma (NPC). However, chemoresistance inevitable develops and the underlying mechanism remains poorly understood. In this study, we identify the arginine methyltransferase PRMT5 as a key gene associated with chemoresistance to paclitaxel in NPC. We demonstrate that PRMT5 facilitated paclitaxel resistance by inducing KCNMB4 expression in nasopharyngeal carcinoma cells. Mechanistically, PRMT5 is recruited to the promoter region of KCNMB4, where it catalyzes H3R2me2s and enhances KCNMB4 expression. Furthermore, elevated levels of PRMT5 or KCNMB4 correlated with poorer survival and higher recurrence rates in NPC patients. Notably, genetic or pharmacological inhibition of PRMT5 significantly sensitized NPC cells to paclitaxel, both in vitro and in vivo. Collectively, these results suggest that the PRMT5-KCNMB4 axis plays a crucial role in mediating chemoresistance in NPC and targeting this axis may provide a promising therapeutic strategy for late-stage NPC patients.

> **中文摘要：**
> 同步化疗是晚期鼻咽癌（NPC）的标准治疗策略。然而，化疗耐药性不可避免地产生，其潜在机制仍知之甚少。在本研究中，我们鉴定出精氨酸甲基转移酶PRMT5是与鼻咽癌紫杉醇耐药相关的关键基因。我们证明PRMT5通过诱导鼻咽癌细胞中KCNMB4的表达来促进紫杉醇耐药。从机制上讲，PRMT5被募集到KCNMB4的启动子区域，在那里它催化H3R2me2s并增强KCNMB4的表达。此外，PRMT5或KCNMB4水平升高与鼻咽癌患者较差的生存率和较高的复发率相关。值得注意的是，在体外和体内，遗传或药理学抑制PRMT5均能显著增敏鼻咽癌细胞对紫杉醇的反应。总之，这些结果表明PRMT5-KCNMB4轴在介导鼻咽癌化疗耐药中起着关键作用，靶向该轴可能为晚期鼻咽癌患者提供一种有前景的治疗策略。

### 第二部分 AI 大师评价

本研究旨在揭示晚期鼻咽癌紫杉醇耐药的新机制。通过分子生物学实验，作者发现精氨酸甲基转移酶PRMT5通过催化KCNMB4启动子区的组蛋白H3R2对称二甲基化（H3R2me2s）上调其表达，从而驱动耐药。该研究创新性地将表观遗传调控与离子通道基因表达联系起来，并提供了靶向PRMT5可逆转耐药的临床前证据。然而，研究主要基于细胞和动物模型，其临床转化潜力及PRMT5抑制剂在人体内的安全性和有效性仍需进一步验证。

---

## 28. 鸟分枝杆菌感染诱导巨噬细胞PD-L1过表达：一种与免疫逃逸相关的潜在机制

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41513601)
**期刊：** Cell death & disease
**PMID：** 41513601
**DOI：** 10.1038/s41419-025-08165-z

### 第一部分 原文与翻译

**英文原标题：** Mycobacterium avium infection induced PD-L1 overexpression in macrophages: a potential involvement with immune escape.

> **英文摘要：**
> Non-tuberculous mycobacteria (NTM) infections are difficult to cure completely with current treatments, and no specific drugs are available. However, recent reports have indicated that immune checkpoint inhibitors may effectively treat pulmonary NTM infections. In this study, we investigated the expression of immune checkpoint molecules in macrophages, the host cells of NTM, and assessed their impact on the microenvironment of infected lesions. Bulk-RNA sequencing and western blot analyses revealed that macrophages infected with Mycobacterium avium, an NTM species, exhibited a pro-inflammatory phenotype and increased PD-L1 expression. Additionally, immunostaining of an NTM-infected mouse model and human tissues showed that increased PD-L1 expression in macrophages was associated with decreased T cell infiltration and increased T cell exhaustion (upregulated PD-1 expression) within infected lesions. These findings suggest that NTM infections evade cellular immunity by enhancing PD-L1 expression in macrophages. Therefore, PD-L1 inhibition may be a promising therapeutic strategy against NTM infections.

> **中文摘要：**
> 非结核分枝杆菌（NTM）感染难以通过现有疗法完全治愈，且缺乏特异性药物。然而，近期报告表明免疫检查点抑制剂可能有效治疗肺部NTM感染。在本研究中，我们探究了NTM宿主细胞——巨噬细胞中免疫检查点分子的表达，并评估了它们对感染病灶微环境的影响。Bulk-RNA测序和蛋白质印迹分析显示，感染了鸟分枝杆菌（一种NTM）的巨噬细胞表现出促炎表型，且PD-L1表达增加。此外，对NTM感染小鼠模型和人组织进行的免疫染色表明，巨噬细胞中PD-L1表达的增加与感染病灶内T细胞浸润减少和T细胞耗竭（PD-1表达上调）相关。这些发现提示，NTM感染通过增强巨噬细胞中的PD-L1表达来逃逸细胞免疫。因此，抑制PD-L1可能是一种有前景的治疗NTM感染的策略。

### 第二部分 AI 大师评价

本研究旨在探究鸟分枝杆菌感染如何通过调控巨噬细胞的免疫检查点分子来影响免疫微环境，从而揭示NTM感染的免疫逃逸机制。研究综合运用了体外分子生物学技术（Bulk-RNA测序、蛋白质印迹）和体内外病理模型（小鼠模型、人组织免疫染色），方法较为全面。核心发现是鸟分枝杆菌感染诱导巨噬细胞高表达PD-L1，并与病灶内T细胞功能抑制（浸润减少、耗竭增加）直接关联，这为理解NTM的致病性提供了新视角。其创新性在于将肿瘤免疫中的PD-1/PD-L1轴与NTM感染机制相联系，并提出了靶向PD-L1的治疗新策略，但研究主要基于相关性证据，其具体的信号通路和体内治疗的有效性仍需后续实验验证。

---

## 29. 纪念：Pelayo Correa 医学博士（1927-2025）。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41513444)
**期刊：** Gut
**PMID：** 41513444
**DOI：** 10.1136/gutjnl-2025-337983

### 第一部分 原文与翻译

**英文原标题：** In memoriam: Pelayo Correa, MD (1927-2025).

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文是一篇纪念性讣告，而非传统的研究论文。其核心目的是缅怀和纪念在胃肠道肿瘤流行病学领域做出开创性贡献的杰出病理学家 Pelayo Correa 博士。文章通过回顾其生平，旨在强调其在胃癌病因学、幽门螺杆菌与胃癌关联以及Correa级联模型等方面的里程碑式发现。其价值在于传承学术遗产，但作为纪念文章，不包含具体的研究方法、数据或新发现，因此不具备传统研究论文的创新性或局限性分析框架。

---

## 30. KRAS突变驱动的CLDN18.2 O-GlcNAc糖基化增强胰腺癌进展并降低CLDN18.2靶向治疗疗效

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41513443)
**期刊：** Gut
**PMID：** 41513443
**DOI：** 10.1136/gutjnl-2025-336277

### 第一部分 原文与翻译

**英文原标题：** KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy.

> **英文摘要：**
> BACKGROUND: CLDN18.2 has emerged as a promising therapeutic target in gastric and gastro-oesophageal junction cancers. However, its clinical efficacy in pancreatic ductal adenocarcinoma (PDAC) has been modest, suggesting the presence of regulatory mechanisms impairing its efficacy. OBJECTIVE: We aim to investigate how O-linked N-acetylglucosaminylation (O-GlcNAcylation) affects CLDN18.2 subcellular localisation, tumour progression and therapeutic resistance in PDAC, while exploring strategies to restore treatment sensitivity. DESIGN: This study used samples from patients with PDAC, along with the following models: humanised patient-derived xenograft (PDX), patient-derived organoids (PDOs), orthotopic PDO xenograft, KPC mice (LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx1-Cre) and KPC-Cldn18.2 knockout (KO) mice. RESULTS: (Kirsten rat sarcoma viral oncogene homolog) mutation and hyperglycaemia cooperatively drive CLDN18.2 O-GlcNAcylation at T204, promoting CLDN18.2 cytoplasmic accumulation. O-GlcNAcylated CLDN18.2 promotes pancreatic cancer migration, invasion and metastases and reduces its sensitivity to anti-CLDN18.2 based targeted therapy. Mechanistically, O-GlcNAcylated CLDN18.2 exhibits reduced binding to PTP1B, leading to enhanced tyrosine phosphorylation. O-GlcNAcylated CLDN18.2 recruits  via SH2 domain, triggering  activation. Genetic (T204A) or pharmacological blockade of O-GlcNAcylation restores CLDN18.2 membrane localisation and suppresses tumour progression. Therapeutically, low-dose MRTX1133 (KRAS inhibitor) reduces O-GlcNAcylation and synergises with CLDN18.2-targeted therapy in KRAS mutant PDAC models with minimal side effects. CONCLUSIONS: KRAS mutations and hyperglycaemia drive O-GlcNAcylation of CLDN18.2 at its C-terminal T204 site. O-GlcNAcylated CLDN18.2 promotes poor prognosis and reduces the effectiveness of CLDN18.2-targeted therapies. Low dose MRTX1133 restores CLDN18.2 membrane localisation by reducing its O-GlcNAcylation and augments CLDN18.2-targeted therapy efficacy, offering a novel combinatorial strategy for KRAS-mutant PDAC.

> **中文摘要：**
> 背景：CLDN18.2已成为胃癌和胃食管结合部癌一个有前景的治疗靶点。然而，其在胰腺导管腺癌（PDAC）中的临床疗效有限，提示存在损害其疗效的调控机制。目的：我们旨在研究O-连接N-乙酰葡糖胺化（O-GlcNAcylation）如何影响PDAC中CLDN18.2的亚细胞定位、肿瘤进展和治疗抵抗，同时探索恢复治疗敏感性的策略。设计：本研究使用了PDAC患者的样本，以及以下模型：人源化患者来源异种移植瘤（PDX）、患者来源类器官（PDOs）、原位PDO异种移植瘤、KPC小鼠（LSL-KrasG12D/+； LSL-Trp53R172H/+； Pdx1-Cre）和KPC-Cldn18.2敲除（KO）小鼠。结果：KRAS（Kirsten大鼠肉瘤病毒癌基因同源物）突变和高血糖协同驱动CLDN18.2在T204位点的O-GlcNAc糖基化，促进CLDN18.2在细胞质中积聚。O-GlcNAc糖基化的CLDN18.2促进胰腺癌的迁移、侵袭和转移，并降低其对基于抗CLDN18.2靶向治疗的敏感性。机制上，O-GlcNAc糖基化的CLDN18.2与PTP1B的结合减少，导致酪氨酸磷酸化增强。O-GlcNAc糖基化的CLDN18.2通过SH2结构域招募，触发激活。遗传学（T204A）或药理学阻断O-GlcNAc糖基化可恢复CLDN18.2的膜定位并抑制肿瘤进展。在治疗方面，低剂量MRTX1133（KRAS抑制剂）可减少O-GlcNAc糖基化，并在KRAS突变PDAC模型中与CLDN18.2靶向治疗产生协同作用，且副作用最小。结论：KRAS突变和高血糖驱动CLDN18.2在其C末端T204位点的O-GlcNAc糖基化。O-GlcNAc糖基化的CLDN18.2促进不良预后并降低CLDN18.2靶向治疗的有效性。低剂量MRTX1133通过减少CLDN18.2的O-GlcNAc糖基化来恢复其膜定位，并增强CLDN18.2靶向治疗的疗效，为KRAS突变PDAC提供了一种新的联合治疗策略。

### 第二部分 AI 大师评价

本研究旨在阐明CLDN18.2靶向疗法在胰腺导管腺癌（PDAC）中疗效不佳的机制，并探索逆转策略。研究通过整合患者样本、多种PDX/PDO模型及基因工程小鼠，系统揭示了KRAS突变与高血糖协同驱动CLDN18.2发生O-GlcNAc糖基化，导致其胞质滞留、功能改变并促进肿瘤恶性进展的核心机制。其创新性在于首次将KRAS信号、代谢异常（高血糖）与靶蛋白翻译后修饰（O-GlcNAcylation）及治疗抵抗联系起来，并提出了“KRAS抑制剂低剂量联合CLDN18.2靶向药”这一具有转化潜力的新策略。局限性在于摘要中部分关键信号通路细节（如招募的具体蛋白）未明确，且临床前模型的疗效需进一步在临床试验中验证。

---

## 31. ROSE12：一种由细胞外三磷酸腺苷激活的新型抗CTLA-4 FcγRs结合增强型抗体，展现出肿瘤选择性调节性T细胞耗竭和抗肿瘤功效，且无系统性免疫激活。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41513409)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41513409
**DOI：** 10.1136/jitc-2025-013397

### 第一部分 原文与翻译

**英文原标题：** ROSE12, a novel anti-CTLA-4 FcγRs binding-enhanced antibody activated by extracellular adenosine triphosphate, shows tumor-selective regulatory T-cell depletion and antitumor efficacy without systemic immune activation.

> **英文摘要：**
> BACKGROUND: Intratumoral regulatory T cells (Tregs) are associated with diminished antitumor immunity and poor prognosis in many cancers, with tumor-infiltrating effector Tregs expressing high levels of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). While Treg depletion is a promising strategy for cancer immunotherapy, systemic Treg depletion may lead to severe autoimmune toxicity. Therefore, to selectively deplete intratumoral Tregs, we used extracellular ATP (exATP), which is highly elevated in solid tumors, as a tumor-selective small molecule. METHODS: We generated ROSE12, a novel anti-CTLA-4 Fc gamma receptors (FcγRs)-binding-enhanced-Fc exATP-dependent switch antibody that reduces Tregs only in the presence of exATP. We evaluated ATP-dependent binding affinity, antibody依赖性细胞毒性 (ADCC) activity in vitro, and antitumor efficacy of monotherapy and combination therapy with anti-programmed death-ligand 1 (PD-L1) in CTLA-4/CD3 double humanized mouse models. Safety profiles were assessed in cynomolgus monkeys. RESULTS: ROSE12 demonstrated ATP concentration-dependent binding to CTLA-4, with strong binding at 100 µmol/L but no binding without ATP. ROSE12 demonstrated stronger exATP-dependent ADCC activity in vitro and preferentially reduced CTLA-4 Tregs over activated conventional T cells. The engineered asymmetric re-engineering technology-Fc (ART-Fc) region, a proprietary Fc engineering technology, showed enhanced binding to activating FcγRIIa and FcγRIIIa while reducing binding to inhibitory FcγRIIb. In mouse models, ROSE12 monotherapy significantly inhibited tumor growth in both conventional and PD-L1 therapy-resistant tumors by reducing intratumoral Tregs and increasing CD8 T-cell infiltration. Combination therapy with anti-PD-L1 showed synergistic antitumor efficacy with enhanced intratumoral CD8 T-cell activation without increasing systemic immune activation. Unlike FcγRs binding-enhanced conventional anti-CTLA-4, ROSE12 did not induce systemic immune activation or colitis symptoms, demonstrating a 30-300-fold wider therapeutic window. The tumor-selective mechanism was confirmed in humanized mouse models, where ROSE12 reduced only intratumoral Tregs while sparing splenic Tregs. In cynomolgus monkeys, ROSE12 was well tolerated even at 30 mg/kg/week compared with the 3-10 mg/kg/week limits for conventional anti-CTLA-4 antibodies such as non-fucosylated ipilimumab and ipilimumab. CONCLUSIONS: These findings support the clinical development of ROSE12 as a tumor-selective Treg-depleting immunotherapy with potential efficacy in programmed cell death protein-1/PD-L1 therapy-resistant patients. The favorable safety profile was attributed to the ATP-dependent binding mechanism that restricts activity to the high-ATP tumor microenvironment. ROSE12 is currently being evaluated in phase I clinical trials (NCT05907980).

> **中文摘要：**
> 背景：肿瘤内调节性T细胞（Tregs）与多种癌症中抗肿瘤免疫力减弱和不良预后相关，肿瘤浸润的效应Tregs高表达细胞毒性T淋巴细胞相关蛋白4（CTLA-4）。虽然耗竭Tregs是癌症免疫治疗的一种有前景的策略，但系统性Treg耗竭可能导致严重的自身免疫毒性。因此，为了选择性耗竭肿瘤内Tregs，我们利用在实体瘤中高度升高的细胞外ATP（exATP）作为一种肿瘤选择性小分子。方法：我们构建了ROSE12，一种新型的抗CTLA-4 Fcγ受体（FcγRs）结合增强型Fc、依赖exATP的开关抗体，它仅在exATP存在时才减少Tregs。我们在CTLA-4/CD3双人源化小鼠模型中评估了其ATP依赖性结合亲和力、体外抗体依赖性细胞毒性（ADCC）活性、以及单药和与抗程序性死亡配体1（PD-L1）联合治疗的抗肿瘤疗效。在食蟹猴中评估了其安全性特征。结果：ROSE12表现出ATP浓度依赖性的CTLA-4结合，在100 µmol/L时结合强，而无ATP时不结合。ROSE12在体外表现出更强的exATP依赖性ADCC活性，并优先减少CTLA-4 Tregs，而非活化的常规T细胞。工程化的非对称再工程技术-Fc（ART-Fc）区域（一种专有的Fc工程技术）显示出对激活性FcγRIIa和FcγRIIIa的结合增强，同时减少了对抑制性FcγRIIb的结合。在小鼠模型中，ROSE12单药治疗通过减少肿瘤内Tregs和增加CD8 T细胞浸润，显著抑制了常规肿瘤和PD-L1治疗耐药肿瘤的生长。与抗PD-L1的联合治疗显示出协同抗肿瘤疗效，增强了肿瘤内CD8 T细胞的活化，而未增加系统性免疫激活。与FcγRs结合增强的常规抗CTLA-4抗体不同，ROSE12未诱导系统性免疫激活或结肠炎症状，显示出30-300倍更宽的治疗窗口。肿瘤选择性机制在人源化小鼠模型中得到证实，ROSE12仅减少肿瘤内Tregs，而保留脾脏Tregs。在食蟹猴中，与传统抗CTLA-4抗体（如非岩藻糖基化伊匹木单抗和伊匹木单抗）的3-10 mg/kg/周限制相比，ROSE12即使在30 mg/kg/周的剂量下也耐受良好。结论：这些发现支持将ROSE12作为一种肿瘤选择性Treg耗竭免疫疗法进行临床开发，该疗法对程序性细胞死亡蛋白-1/PD-L1治疗耐药患者具有潜在疗效。其良好的安全性特征归因于ATP依赖性结合机制，该机制将其活性限制在高ATP的肿瘤微环境中。ROSE12目前正在I期临床试验（NCT05907980）中进行评估。

### 第二部分 AI 大师评价

本研究旨在开发一种肿瘤选择性调节性T细胞（Treg）耗竭疗法，以克服传统抗CTLA-4抗体系统性免疫激活导致的严重毒性。其核心创新在于设计了一种依赖肿瘤微环境中高浓度细胞外ATP（exATP）激活的“开关”抗体ROSE12，并融合了增强FcγR结合以提升ADCC效应的专有Fc工程技术（ART-Fc）。研究发现，ROSE12在临床前模型中实现了精准的瘤内Treg耗竭、强效抗肿瘤活性（包括对PD-L1耐药肿瘤）以及与抗PD-L1的协同作用，同时显著拓宽了治疗窗口（30-300倍），且在食蟹猴中表现出优异的安全性。该策略巧妙地利用肿瘤微环境特征实现靶向激活，是提高免疫检查点抑制剂安全性的重要突破，但其最终疗效与安全性仍需正在进行的I期临床试验验证。

---

## 32. 推进卵巢癌过继性T细胞疗法：障碍、创新与新兴平台。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41513408)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41513408
**DOI：** 10.1136/jitc-2025-013285

### 第一部分 原文与翻译

**英文原标题：** Advancing adoptive T cell therapy in ovarian cancer: barriers, innovations, and emerging platforms.

> **英文摘要：**
> Adoptive cell therapy (ACT) has demonstrated curative potential in select cancers, but its translation to solid tumors such as ovarian cancer (OC) has been hindered by multiple factors, including tumor heterogeneity, immune exclusion, and a profoundly immunosuppressive tumor microenvironment. This review provides a comprehensive analysis of current ACT modalities, including tumor-infiltrating lymphocytes, T cell receptor-engineered, and chimeric antigen receptor-T cell therapies, as well as emerging approaches such as bispecific T cell engager (BiTE)-secreting T cells, dual-targeting platforms, and synthetic antigen receptors. We examine their application in OC and contextualize relevant findings using insights from other solid tumors. Key barriers, including limited T cell persistence, antigen escape, and T cell exhaustion, are explored alongside strategies to enhance efficacy through cytokine armoring, checkpoint modulation, metabolic reprogramming, and gene editing. We further highlight innovations in safety engineering, including logic-gated and self-regulating synthetic circuits, to mitigate toxicity and improve precision. Additional attention is given to the evolving role of allogeneic products and in vivo engineering as scalable solutions. Finally, we emphasize the critical value of integrating high-dimensional tools such as spatial transcriptomics, single-cell profiling, and machine learning to refine ACT design, identify biomarkers of response, and support patient selection and stratification. Collectively, these advances offer a roadmap for overcoming the unique immunologic barriers to ACT in OC and accelerating the development of more potent, durable, and personalized T cell-based strategies.

> **中文摘要：**
> 过继性细胞疗法（ACT）已在部分癌症中显示出治愈潜力，但其在卵巢癌（OC）等实体瘤中的应用受到多种因素的阻碍，包括肿瘤异质性、免疫排斥和深度免疫抑制的肿瘤微环境。本综述全面分析了当前的ACT模式，包括肿瘤浸润淋巴细胞、T细胞受体工程化和嵌合抗原受体T细胞疗法，以及新兴方法，如分泌双特异性T细胞衔接器（BiTE）的T细胞、双靶向平台和合成抗原受体。我们探讨了它们在OC中的应用，并借鉴其他实体瘤的研究结果来阐释相关发现。文章探讨了关键障碍，包括T细胞持久性有限、抗原逃逸和T细胞耗竭，同时分析了通过细胞因子装甲、检查点调节、代谢重编程和基因编辑来提高疗效的策略。我们进一步强调了安全工程方面的创新，包括逻辑门控和自我调节的合成回路，以减轻毒性并提高精准性。此外，还关注了同种异体产品和体内工程作为可扩展解决方案的演变作用。最后，我们强调了整合空间转录组学、单细胞分析和机器学习等高维工具对于优化ACT设计、识别反应生物标志物以及支持患者选择和分层的关键价值。总之，这些进展为克服ACT在OC中面临的独特免疫障碍，并加速开发更有效、更持久、更个性化的T细胞策略提供了路线图。

### 第二部分 AI 大师评价

本综述旨在系统梳理过继性T细胞疗法（ACT）在卵巢癌（OC）这一实体瘤领域面临的挑战与最新进展。文章方法上，全面评述了现有及新兴的ACT技术平台，并结合其他实体瘤的经验进行深入分析。核心发现是，通过剖析T细胞持久性、抗原逃逸等关键障碍，并整合细胞因子装甲、逻辑门控安全开关、同种异体平台以及高维组学工具等多种策略，有望克服OC的免疫抑制微环境。其创新性在于构建了一个从识别障碍到工程化解决方案（包括疗效增强与安全控制）再到利用多组学数据指导个性化治疗的完整路线图，但作为综述，其结论仍需未来临床前与临床研究数据的进一步验证。

---

## 33. 构建超越当前尺寸限制的单载体逻辑门控CAR-T细胞

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41513407)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41513407
**DOI：** 10.1136/jitc-2025-012318

### 第一部分 原文与翻译

**英文原标题：** Engineering single-vector logic-gated CAR T cells with transgene sizes beyond current limitations.

> **英文摘要：**
> BACKGROUND: Engineering chimeric antigen receptor (CAR) T cells with logic-gated synthetic Notch (synNotch) receptor circuits can enhance specificity and mitigate on-target/off-tumor toxicity. However, the conventional synNotch system uses two lentiviral vectors encoding the synNotch receptor and inducible CAR, requiring dual transduction and cell分选， which limits clinical translation. Integrating the synNotch-CAR circuit into a single lentiviral vector could overcome this limitation, yet manufacturing CAR T cells with large transgenes remains challenging, as increasing transgene size drastically reduces lentiviral titers and T cell transduction efficiency. Current production workflows compensate for low transduction efficiency by sorting transduced cells, further impeding clinical translation. Consequently, these constraints have limited the broader development of synNotch-CAR T cell therapies. METHODS: We engineered a single-vector synNotch (svsNotch) system that integrates all components of the conventional dual-vector circuit into one lentiviral vector to facilitate clinical translation. To overcome the low lentiviral titers and T cell transduction efficiency caused by the large svsNotch transgene, we established an optimized CAR T cell production workflow for effector T cells with large lentiviral transgenes. RESULTS: Our optimized workflow increased T cell transduction rates by up to 14.8-fold and enabled the production of effector T cells with lentiviral transgenes exceeding the effective packaging capacity limit of 9.2 kb. As a proof of concept, we engineered human epidermal growth factor receptor 2 (HER2)-mesothelin (MSLN) svsNotch (9.2 kb), in which a synNotch receptor targeting HER2 regulates the expression of a second-generation 4-1BBζ CAR against MSLN to enable selective targeting of double-positive HER2MSLN ovarian tumors. In vitro, HER2-MSLN svsNotch T cells demonstrated superior specificity to conventional dual-vector synNotch-CAR T cells, with selective cytotoxicity against HER2MSLN but not HER2MSLN tumor cells. To enable in vivo monitoring, we engineered HER2-MSLN-click beetle green (CBG) svsNotch (10.1 kb) incorporating CBG luciferase. In mouse models using constitutive CAR T cells as controls, HER2-MSLN-CBG svsNotch T cells exhibited minimal cytotoxicity in the absence of HER2 and superior efficacy against HER2MSLN and HER2MSLN tumors. CONCLUSION: These data establish a framework for engineering logic-gated single-vector immunotherapies and provide an optimized workflow for generating CAR T cells with transgenes that exceed current size limitations.

> **中文摘要：**
> 背景：利用逻辑门控合成Notch（synNotch）受体回路设计嵌合抗原受体（CAR）T细胞可以增强特异性并减轻靶上/脱瘤毒性。然而，传统的synNotch系统使用两个分别编码synNotch受体和诱导型CAR的慢病毒载体，需要进行双重转导和细胞分选，这限制了临床转化。将synNotch-CAR回路整合到单个慢病毒载体中可以克服这一限制，但制造携带大转基因的CAR-T细胞仍然具有挑战性，因为增加转基因大小会急剧降低慢病毒滴度和T细胞转导效率。当前的生产流程通过分选转导的细胞来补偿低转导效率，进一步阻碍了临床转化。因此，这些限制制约了synNotch-CAR T细胞疗法的更广泛发展。方法：我们设计了一个单载体synNotch（svsNotch）系统，将传统双载体回路的所有组件整合到一个慢病毒载体中，以促进临床转化。为了克服由大svsNotch转基因引起的低慢病毒滴度和T细胞转导效率，我们为携带大慢病毒转基因的效应T细胞建立了一个优化的CAR-T细胞生产流程。结果：我们的优化流程将T细胞转导率提高了高达14.8倍，并实现了生产携带超过9.2 kb有效包装容量限制的慢病毒转基因的效应T细胞。作为概念验证，我们构建了靶向人表皮生长因子受体2（HER2）-间皮素（MSLN）的svsNotch（9.2 kb），其中靶向HER2的synNotch受体调控一个针对MSLN的第二代4-1BBζ CAR的表达，从而实现对双阳性HER2MSLN卵巢肿瘤的选择性靶向。在体外，HER2-MSLN svsNotch T细胞表现出优于传统双载体synNotch-CAR T细胞的特异性，对HER2MSLN而非HER2MSLN肿瘤细胞具有选择性细胞毒性。为了实现体内监测，我们构建了整合了CBG荧光素酶的HER2-MSLN-点击甲虫绿（CBG）svsNotch（10.1 kb）。在使用组成型CAR T细胞作为对照的小鼠模型中，HER2-MSLN-CBG svsNotch T细胞在缺乏HER2的情况下表现出最小的细胞毒性，并对HER2MSLN和HER2MSLN肿瘤具有更优的疗效。结论：这些数据为构建逻辑门控单载体免疫疗法建立了一个框架，并为生成转基因超过当前尺寸限制的CAR-T细胞提供了一个优化的工作流程。

### 第二部分 AI 大师评价

本研究旨在解决逻辑门控synNotch-CAR T细胞疗法临床转化的关键瓶颈。核心创新在于开发了单载体synNotch系统并配套优化了生产流程，成功克服了大转基因（>9.2 kb）导致的慢病毒包装与T细胞转导效率低下的难题。研究证实，该单载体系统在体外和体内均展现出优于传统双载体系统的特异性与疗效，为复杂、安全的下一代CAR-T疗法开发提供了可行的技术框架。然而，研究主要聚焦于技术可行性验证，其长期安全性、在不同肿瘤模型中的普适性以及规模化生产的稳定性仍需进一步评估。

---

## 34. S1826研究中纳武利尤单抗-AVD与维布妥昔单抗-AVD治疗青少年晚期经典霍奇金淋巴瘤的三年随访结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41512237)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41512237
**DOI：** 10.1200/JCO-25-00203

### 第一部分 原文与翻译

**英文原标题：** Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin-AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826.

> **英文摘要：**
> We present a subset分析 on the adolescent cohort of the S1826 randomized phase three trial, comparing nivolumab, doxorubicin, vinblastine, dacarbazine (N-AVD) to brentuximab vedotin-AVD (BV-AVD) in newly diagnosed advanced-stage (AS, stages III and IV) classic Hodgkin lymphoma (cHL). Among 994 patients enrolled, 24% (n = 240) were age 12-17 years. The 3-year progression-free survival (PFS) was significantly higher in the N-AVD group (93% [95% CI, 87 to 96]) compared with the BV-AVD group (82% [95% CI, 73 to 88]; hazard ratio, 0.37 [95% CI, 0.17 to 0.80]). One N-AVD and two BV-AVD patients received protocol-specified residual site radiotherapy (RT). Rates of febrile neutropenia and sepsis were low in both groups. Severe immune-related adverse events were infrequent, although thyroid dysfunction was seen in 7% with N-AVD. Sensory neuropathy (grade ≥2) was more frequent with BV-AVD (14%  7%) by clinician report. Although premature discontinuation of therapy was reported in 12 N-AVD patients and four BV-AVD patients, no PFS events were noted in the N-AVD group. Patient-reported outcomes indicated less toxicity with N-AVD. N-AVD demonstrated high 3-year PFS in adolescents with AS cHL, with minimal RT use. S1826 exemplifies the benefits of harmonized clinical trial protocols, resulting in timely access to novel agents for adolescents.

> **中文摘要：**
> 本文报告了S1826随机三期试验中青少年队列的亚组分析，该研究比较了纳武利尤单抗联合多柔比星、长春碱、达卡巴嗪（N-AVD）与维布妥昔单抗联合AVD（BV-AVD）在新诊断晚期（AS，III期和IV期）经典霍奇金淋巴瘤（cHL）中的疗效。在入组的994名患者中，24%（n = 240）年龄为12-17岁。N-AVD组的3年无进展生存期（PFS）显著高于BV-AVD组（93% [95% CI, 87 to 96] 对比 82% [95% CI, 73 to 88]；风险比，0.37 [95% CI, 0.17 to 0.80]）。一名N-AVD患者和两名BV-AVD患者接受了方案指定的残留部位放疗（RT）。两组发热性中性粒细胞减少和败血症的发生率均较低。严重的免疫相关不良事件不常见，尽管N-AVD组有7%的患者出现甲状腺功能障碍。根据临床医生报告，BV-AVD组感觉神经病变（≥2级）更常见（14% 对比 7%）。尽管报告了12名N-AVD患者和4名BV-AVD患者提前终止治疗，但N-AVD组未观察到PFS事件。患者报告结局表明N-AVD的毒性更低。N-AVD在青少年晚期cHL患者中显示出较高的3年PFS，且放疗使用极少。S1826研究体现了统一临床试验方案的优势，使青少年能够及时获得新型药物。

### 第二部分 AI 大师评价

本研究对S1826三期试验的青少年亚组进行了分析，核心目的是比较免疫检查点抑制剂（纳武利尤单抗）与抗体药物偶联物（维布妥昔单抗）联合AVD化疗在青少年晚期经典霍奇金淋巴瘤一线治疗中的疗效与安全性。研究发现，N-AVD方案在3年无进展生存率上显著优于BV-AVD方案（93% vs 82%），且患者报告的毒性更低，放疗使用极少，展现了免疫治疗在青少年患者中的巨大潜力。其创新性在于为这一特定年龄组提供了高级别循证医学证据，并体现了将青少年纳入大型成人试验的“协调方案”优势，加速了新疗法的可及性；局限性在于作为亚组分析，样本量相对有限，且长期生存数据和特定毒性（如甲状腺功能异常）的长期影响仍需更长时间随访。

---

## 35. 结直肠癌奥沙利铂-氟嘧啶辅助化疗3个月对比6个月：SCOT国际随机III期非劣效性试验的最终结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41512219)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41512219
**DOI：** 10.1200/JCO-25-00621

### 第一部分 原文与翻译

**英文原标题：** Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial.

> **英文摘要：**
> Adjuvant chemotherapy for colorectal cancer (CRC) with oxaliplatin and fluoropyrimidine was traditionally given for 6 months but is associated with cumulative peripheral neuropathy. The SCOT study (ISRCTN59757862) was an international, randomized, phase III, noninferiority trial investigating treatment reduction from 6 to 3 months. It originally reported noninferior disease-free survival with reduced toxicity and improved quality of life for 3 months of treatment in 6,088 patients. Here, we report overall survival (OS) with 38 months of additional follow-up. Patients with high-risk stage II and stage III CRC were assigned (1:1) to receive 3 or 6 months of either capecitabine and oxaliplatin (CAPOX) or infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX; bolus and infused fluorouracil with oxaliplatin) that were selected before random assignment. With a median of 113 months follow-up and 1,255 OS events, 5-year OS for 3 versus 6 months of treatment was 82.4% in both groups (hazard ratio, 0.96; 95% CI, 0.8 to 1.07), proving noninferiority of 3 months of treatment. Noninferiority of 3 months of treatment for OS was also shown in 1,087 patients with rectal cancer. The duration effect is regimen-dependent with noninferiority shown for CAPOX but not for FOLFOX. In summary, SCOT has shown noninferiority for OS with 3 months of adjuvant chemotherapy treatment, which should be recommended for most patients.

> **中文摘要：**
> 结直肠癌（CRC）的奥沙利铂联合氟嘧啶辅助化疗传统上给予6个月，但会导致累积性外周神经毒性。SCOT研究（ISRCTN59757862）是一项国际、随机、III期、非劣效性试验，旨在探究将治疗时间从6个月缩短至3个月的效果。该研究最初报告了在6，088名患者中，3个月治疗在无病生存方面非劣效，且毒性降低、生活质量改善。在此，我们报告了额外38个月随访后的总生存期（OS）结果。高风险II期和III期CRC患者被（1：1）分配接受3个月或6个月的卡培他滨联合奥沙利铂（CAPOX）或输注氟尿嘧啶、亚叶酸钙联合奥沙利铂（FOLFOX；推注及输注氟尿嘧啶联合奥沙利铂）方案，方案在随机分组前选定。中位随访113个月，发生1255例OS事件后，3个月与6个月治疗组的5年OS均为82.4%（风险比，0.96；95% CI，0.8至1.07），证明了3个月治疗的非劣效性。在1087名直肠癌患者中也显示了3个月治疗在OS方面的非劣效性。治疗时长效果依赖于具体方案，CAPOX方案显示了非劣效性，而FOLFOX方案则未显示。总之，SCOT研究证明了3个月辅助化疗在总生存期上的非劣效性，应推荐给大多数患者。

### 第二部分 AI 大师评价

SCOT试验的最终OS分析是结直肠癌辅助化疗领域一项里程碑式的研究。其核心目的是通过大型III期非劣效性设计，验证将传统6个月奥沙利铂-氟嘧啶方案缩短至3个月是否影响长期生存。研究发现，在中位随访近10年后，3个月与6个月治疗的5年OS率完全相同（均为82.4%），证实了缩短疗程在总生存上的非劣效性，且该结论在直肠癌亚组中同样成立。其重要创新在于为“去强化”治疗提供了最高级别的生存证据，有望显著减少神经毒性等长期副作用，改善患者生活质量；主要局限性在于疗效具有方案依赖性，非劣效性结论明确适用于CAPOX方案，但对FOLFOX方案的支持证据不足，提示临床决策需结合具体用药方案进行个体化考量。

---

## 36. 精准肿瘤学2.0：基于表达的液体活检引导“魔法子弹”。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41512214)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41512214
**DOI：** 10.1200/JCO-25-01983

### 第一部分 原文与翻译

**英文原标题：** Precision Oncology 2.0: Guiding Magic Bullets With Expression-Based Liquid Biopsy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文标题提出了“精准肿瘤学2.0”的概念，其核心目的是探讨如何利用基于表达的液体活检技术来更精准地指导靶向治疗（即“魔法子弹”）。该方法强调了从传统的基因组分析向转录组或蛋白表达谱分析的演进，旨在通过无创的液体活检动态监测肿瘤的分子特征，以优化治疗决策。其创新性在于将液体活检的应用维度从基因突变检测扩展到基因表达层面，有望克服肿瘤异质性和耐药性挑战。然而，由于摘要不可用，该技术的具体验证数据、临床实用性及潜在的局限性（如检测灵敏度、标准化问题）尚不明确。

---

## 37. 小叶乳腺癌中MDC1相互作用的改变与DNA修复功能障碍赋予其对PARP抑制剂的敏感性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41512199)
**期刊：** Cancer research
**PMID：** 41512199
**DOI：** 10.1158/0008-5472.CAN-25-1217

### 第一部分 原文与翻译

**英文原标题：** Altered MDC1 Interactions and Dysfunctional DNA Repair in Lobular Breast Cancer Confers Sensitivity to PARP Inhibition.

> **英文摘要：**
> Invasive lobular carcinoma of the breast (ILC) is typically estrogen receptor α (ER)-positive and presents with biomarkers of anti-estrogen sensitive disease. Unfortunately, patients with ILC face particularly poor long-term outcomes with high recurrence risk, suggesting a divergent endocrine response and ER function in ILC compared to other breast cancers. ER is co-regulated by the DNA repair protein MDC1 specifically in ILC cells, driving distinct ER activity. Here, we profiled the MDC1 interactome to examine how MDC1 regulates ER activity and DNA repair function in ILC. MDC1-associated proteins in ILC cells mirrored a "BRCA-like" state lacking key homologous recombination (HR) proteins, consistent with HR dysfunction but distinct from classic "BRCAness". Single-cell transcriptome and DNA repair activity analyses, along with DNA repair signaling and functional data, substantiated dysfunctional induction and execution of HR in ILC cells. In parallel, ILC tumor data were consistent with a form of HR dysfunction distinct from overt HR deficiency, lacking BRCA-like genomic scarring but showing elevated signatures of PARP inhibitor sensitivity. Treatment with the PARP inhibitor talazoparib produced a durable growth suppression both in vitro and in multiple ILC xenografts in vivo. Together, these findings reveal that ILC-specific ER:MDC1 activity comes at the cost of DNA repair dysfunction, which may be therapeutically targetable.

> **中文摘要：**
> 乳腺浸润性小叶癌（ILC）通常为雌激素受体α（ER）阳性，并表现出抗雌激素敏感疾病的生物标志物。不幸的是，ILC患者面临特别差的长期预后，复发风险高，这表明与其他乳腺癌相比，ILC的内分泌反应和ER功能存在差异。在ILC细胞中，ER受到DNA修复蛋白MDC1的特异性共调控，驱动了独特的ER活性。在此，我们分析了MDC1的相互作用组，以探究MDC1如何调控ILC中的ER活性和DNA修复功能。ILC细胞中与MDC1相关的蛋白质反映了一种缺乏关键同源重组（HR）蛋白的“BRCA样”状态，这与HR功能障碍一致，但又不同于经典的“BRCAness”。单细胞转录组和DNA修复活性分析，以及DNA修复信号传导和功能数据，证实了ILC细胞中HR的诱导和执行功能失调。同时，ILC肿瘤数据与一种不同于明显HR缺陷的HR功能障碍形式相符，其缺乏BRCA样的基因组疤痕，但显示出PARP抑制剂敏感性特征升高。使用PARP抑制剂他拉唑帕尼进行治疗，在体外和多个ILC异种移植模型中均产生了持久的生长抑制。总之，这些发现揭示了ILC特异性的ER:MDC1活性是以DNA修复功能障碍为代价的，而这可能成为治疗靶点。

### 第二部分 AI 大师评价

本研究旨在揭示乳腺浸润性小叶癌（ILC）中ER活性与DNA修复功能失调之间的独特联系。通过分析MDC1相互作用组，结合单细胞转录组、DNA修复活性及信号通路等多维度数据，研究发现ILC细胞存在一种独特的、非经典的HR功能障碍状态，其特征是缺乏关键HR蛋白但无典型基因组疤痕，并表现出对PARP抑制剂的敏感性。其创新性在于将ILC特定的ER调控机制（通过MDC1）与一种新型的“BRCA样”HR功能障碍联系起来，为这类通常ER阳性但预后不佳的乳腺癌提供了新的治疗思路（PARP抑制剂）。局限性在于研究主要基于机制探索和临床前模型，其临床转化效果和患者筛选标准仍需进一步验证。

---

## 38. MTAP缺失在肿瘤发生中的作用：一种合成致死场景。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41512197)
**期刊：** Cancer research
**PMID：** 41512197
**DOI：** 10.1158/0008-5472.CAN-25-2126

### 第一部分 原文与翻译

**英文原标题：** MTAP Deletion in Oncogenesis: A Synthetic Lethality Scenario.

> **英文摘要：**
> Homozygous deletions in the gene encoding methylthioadenosine phosphorylase (MTAP) occur in ~10% of patients with cancer, including up to 45% in some tumor types, and may be associated with poor prognosis. MTAP deficiency causes accumulation of its catabolic target methylthioadenosine (MTA) that outcompetes S-adenosyl methionine (SAM) for binding to protein arginine methyltransferase 5 (PRMT5), partially inhibiting PRMT5 activity as a posttranslational regulator of a variety of critical cellular functions. Prior anticancer treatments developed to target PRMT5 exhibited high rates of dose-limiting hematologic toxicities because of a lack of selectivity for tumor cells. More recently, several agents have been developed that exploit the vulnerability of MTAP-deleted cancer cells to further inhibition of the PRMT5 pathway, selectively inducing synthetic lethality in those cancer cells. MTA-cooperative PRMT5 inhibitors such as BMS-986504/MRTX1719 and AMG 193 target the PRMT5-MTA complex, while inhibitors of the SAM synthetase methionine adenosyl transferase 2A (MAT2A), such as IDE397, deprive PRMT5 of its methyl donor SAM. In this review article, we summarize the mechanisms of action, preclinical data, and clinical data available thus far for these novel classes of oncology precision medicine and discuss potential future directions relevant to MTAP deletion as a promising synthetic lethal vulnerability for cancer therapy.

> **中文摘要：**
> 编码甲基硫代腺苷磷酸化酶（MTAP）的基因发生纯合性缺失，见于约10%的癌症患者，在某些肿瘤类型中比例高达45%，且可能与不良预后相关。MTAP缺陷导致其分解代谢靶标甲基硫代腺苷（MTA）积累，MTA会竞争性取代S-腺苷甲硫氨酸（SAM）与蛋白精氨酸甲基转移酶5（PRMT5）的结合，从而部分抑制PRMT5作为多种关键细胞功能翻译后调节因子的活性。先前开发的靶向PRMT5的抗癌治疗由于缺乏对肿瘤细胞的选择性，表现出高比例的剂量限制性血液学毒性。最近，已开发出多种药物，利用MTAP缺失的癌细胞对PRMT5通路进一步抑制的脆弱性，选择性地在这些癌细胞中诱导合成致死效应。MTA协同性PRMT5抑制剂（如BMS-986504/MRTX1719和AMG 193）靶向PRMT5-MTA复合物，而SAM合成酶甲硫氨酸腺苷转移酶2A（MAT2A）抑制剂（如IDE397）则剥夺PRMT5的甲基供体SAM。在这篇综述文章中，我们总结了这些新型肿瘤精准医学药物的作用机制、临床前数据和迄今为止可获得的临床数据，并讨论了与MTAP缺失作为癌症治疗中一个有前景的合成致死脆弱性相关的潜在未来方向。

### 第二部分 AI 大师评价

本文是一篇关于MTAP缺失作为合成致死靶点的综述。其核心目的是系统阐述MTAP缺失如何通过MTA积累抑制PRMT5活性，从而为开发选择性靶向MTAP缺失肿瘤的精准疗法提供理论基础。文章创新性地总结了两类新兴药物策略：靶向PRMT5-MTA复合物的协同抑制剂和剥夺PRMT5甲基供体SAM的MAT2A抑制剂，旨在克服早期PRMT5抑制剂的选择性差和毒性高的问题。然而，作为一篇综述，其内容主要基于现有文献整合，缺乏原创性实验数据，且所提及的临床数据可能仍处于早期阶段，其长期疗效和安全性有待进一步验证。

---

## 39. KLF5激活通过促进恶性转化驱动肺鳞状细胞癌的发生发展。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41512183)
**期刊：** Cancer research
**PMID：** 41512183
**DOI：** 10.1158/0008-5472.CAN-25-2139

### 第一部分 原文与翻译

**英文原标题：** KLF5 Activation Promotes Malignant Transformation to Drive Development of Lung Squamous Cell Carcinoma.

> **英文摘要：**
> Tumorigenesis is a multistep process requiring alterations in various gene expression programs. The transcription factor KLF5 is frequently genomically amplified and activated in multiple epithelial cancers, highlighting the need to define its role in the transformation of normal epithelium to cancer. Here, we used genetically engineered organoids to identify the function of KLF5 in tumorigenesis of multiple endodermal epithelial cancers. KLF5 activation drove a series of morphological and molecular events during the stepwise transformation of normal airway epithelium towards lung squamous cell carcinoma (LUSC) by remodeling protein biosynthesis and energy metabolism. Inhibition of ribosome biogenesis and oxidative phosphorylation attenuated the malignant progression of LUSC driven by KLF5. In summary, this study identified KLF5 as a crucial transcriptional modulator in LUSC oncogenesis and indicated that KLF5-activated LUSC may be therapeutically vulnerable to inhibition of ribosome biogenesis and oxidative phosphorylation.

> **中文摘要：**
> 肿瘤发生是一个多步骤过程，需要多种基因表达程序的改变。转录因子KLF5在多种上皮癌中常发生基因组扩增和激活，这凸显了明确其在正常上皮向癌症转化中作用的必要性。本研究利用基因工程类器官模型，旨在确定KLF5在多种内胚层上皮癌发生中的功能。KLF5激活通过重塑蛋白质生物合成和能量代谢，在正常气道上皮向肺鳞状细胞癌（LUSC）的逐步转化过程中驱动了一系列形态学和分子事件。抑制核糖体生物合成和氧化磷酸化可减弱KLF5驱动的LUSC恶性进展。总之，本研究确定了KLF5是LUSC癌变过程中的关键转录调节因子，并表明KLF5激活的LUSC可能在治疗上易受核糖体生物合成和氧化磷酸化抑制的影响。

### 第二部分 AI 大师评价

本研究核心目的是阐明转录因子KLF5在肺鳞癌（LUSC）发生中的具体作用机制。研究采用基因工程类器官模型，模拟了从正常气道上皮到LUSC的逐步转化过程，方法学上具有创新性。关键发现是，KLF5激活通过重塑蛋白质合成与能量代谢，驱动恶性转化，并证实抑制这两个过程（核糖体生物合成与氧化磷酸化）可有效遏制KLF5驱动的肿瘤进展。其创新性在于将KLF5的功能与特定代谢重编程直接关联，并提出了潜在的治疗靶点；局限性在于研究主要基于类器官模型，其结论在体内复杂微环境中的普适性有待进一步验证。

---

## 40. 辐射通过GPI锚定增强CD24膜转运介导抗肿瘤免疫逃逸。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41512182)
**期刊：** Cancer research
**PMID：** 41512182
**DOI：** 10.1158/0008-5472.CAN-25-2616

### 第一部分 原文与翻译

**英文原标题：** Radiation-Enhanced CD24 Membrane Trafficking via GPI Anchoring Mediates Anti-Tumor Immune Evasion.

> **英文摘要：**
> Radiotherapy plays a central role in cancer treatment, and the immunostimulatory effects of radiotherapy have been increasingly recognized. A better understanding of the mechanisms underlying post-radiation immune escape is needed to help overcome radioresistance. Here, we identified that irradiated tumor cells exploit the ANAPC5/GPAA1 axis to elevate surface expression of the "don't eat me" signal CD24, inducing phagocytosis resistance and immune evasion. Mechanistically, radiation inhibited the APC/C complex, reducing ANAPC5-mediated ubiquitination of GPAA1, a catalytic subunit of glycosylphosphatidylinositol (GPI) transamidase. The subsequent accumulation of GPAA1 facilitated GPI anchoring, thereby enhancing CD24 membrane localization. Accordingly, ablation of GPAA1 or CD24 significantly potentiated the local antitumor effects of radiotherapy across multiple preclinical models, dependent on T cells and macrophages. Notably, CD24 deficiency also stimulated abscopal effects, suppressing the growth of non-irradiated tumors. Overall, this study elucidates a mechanism of radiotherapy-mediated upregulation of the innate immune checkpoint CD24, offering perspectives on radiation-induced immune escape and presenting a strategy to improve radiotherapy efficacy.

> **中文摘要：**
> 放射治疗在癌症治疗中发挥着核心作用，其免疫刺激效应也日益得到认可。为了更好地克服放射抵抗，需要深入理解放疗后免疫逃逸的机制。本研究发现，受辐照的肿瘤细胞利用ANAPC5/GPAA1轴来提升“别吃我”信号CD24的表面表达，从而诱导抗吞噬作用和免疫逃逸。从机制上讲，辐射抑制了APC/C复合物，减少了ANAPC5介导的糖基磷脂酰肌醇（GPI）转酰胺酶催化亚基GPAA1的泛素化。GPAA1的后续积累促进了GPI锚定，从而增强了CD24的膜定位。因此，在多种临床前模型中，敲除GPAA1或CD24能显著增强放疗的局部抗肿瘤效果，且该效果依赖于T细胞和巨噬细胞。值得注意的是，CD24的缺失还能刺激远端效应，抑制未受照射肿瘤的生长。总之，本研究阐明了放疗介导的先天免疫检查点CD24上调的机制，为理解辐射诱导的免疫逃逸提供了视角，并提出了一种提高放疗疗效的策略。

### 第二部分 AI 大师评价

本研究旨在揭示放疗后肿瘤细胞发生免疫逃逸的新机制，以克服放射抵抗。研究者通过分子生物学和多种临床前模型，发现辐射通过抑制APC/C-ANAPC5，稳定GPAA1，进而增强CD24的GPI锚定与膜定位，使其发挥“别吃我”信号功能。该发现创新性地将DNA损伤应答（APC/C抑制）与先天免疫检查点（CD24）的膜转运调控联系起来，并证明靶向该轴可增强局部及远端抗肿瘤疗效，为联合治疗提供了新靶点。局限性在于其临床转化潜力及在人体肿瘤微环境中的验证尚待进一步研究。

---

## 41. 模拟三级淋巴结的自转化水凝胶激活cGAS-STING通路以增强抗肿瘤免疫治疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41512068)
**期刊：** Science advances
**PMID：** 41512068
**DOI：** 10.1126/sciadv.adz5078

### 第一部分 原文与翻译

**英文原标题：** Self-transforming hydrogel mimicking tertiary lymph nodes to activate cGAS-STING pathway for enhanced antitumor immunotherapy.

> **英文摘要：**
> The nonspecific distribution of tertiary lymph node (TLS)-inducing drugs may trigger autoimmune diseases. We developed a self-transforming chitosan hydrogel to act as a biomimetic TLS. The chitosan hydrogel solution was peritumorally injected in bacteria-colonized tumors in mice followed by the rapid in situ gelation. After killing tumor cells and intratumoral bacteria by doxorubicin and cefotaxime, the hydrogel efficiently adsorbed bacterial pathogen-associated molecular patterns, tumor cell-derived damage-associated molecular patterns, and tumor-associated antigens. These danger signals greatly potentiated immune cell recruitment into the hydrogel and sufficiently activated dendritic cells (DCs) by the absorbed DNA-mediated cGAS-STING activation. The activated DCs converted T cells into cytotoxic T cells, and these activated immune cells migrated through the pores of hydrogels into the tumor tissues, effectively remodeling the immunosuppressive microenvironment, thereby inhibiting the tumor growth and metastasis. These findings demonstrate a previously unidentified method to establish a safe, easy-to-control, and effective biomimetic TLS that offers a promising strategy for updating current combined immunotherapy against various tumors.

> **中文摘要：**
> 诱导三级淋巴结（TLS）形成的药物其非特异性分布可能引发自身免疫性疾病。我们开发了一种自转化的壳聚糖水凝胶作为仿生TLS。将壳聚糖水凝胶溶液注射到小鼠细菌定植肿瘤的瘤周，随后发生快速原位凝胶化。在用阿霉素和头孢噻肈杀死肿瘤细胞和瘤内细菌后，水凝胶高效吸附了细菌病原体相关分子模式、肿瘤细胞来源的损伤相关分子模式和肿瘤相关抗原。这些危险信号极大地促进了免疫细胞向水凝胶内的募集，并通过吸附的DNA介导的cGAS-STING激活充分激活了树突状细胞（DCs）。被激活的DCs将T细胞转化为细胞毒性T细胞，这些被激活的免疫细胞通过水凝胶的孔隙迁移到肿瘤组织中，有效重塑了免疫抑制微环境，从而抑制了肿瘤生长和转移。这些发现展示了一种先前未知的、用于建立安全、易控且有效的仿生TLS的方法，为更新当前针对多种肿瘤的联合免疫疗法提供了一种有前景的策略。

### 第二部分 AI 大师评价

本研究旨在解决三级淋巴结（TLS）诱导药物非特异性分布带来的自身免疫风险，创新性地开发了一种自转化壳聚糖水凝胶作为局部、可控的仿生TLS。其核心方法是将水凝胶注射至瘤周，原位捕获肿瘤细胞和细菌裂解后释放的多种危险信号（PAMPs、DAMPs、TAAs），并通过cGAS-STING通路高效激活树突状细胞，进而驱动T细胞免疫，重塑肿瘤微环境。该策略巧妙地将局部药物递送、危险信号富集与固有免疫激活相结合，为实体瘤免疫治疗提供了一种新颖且具转化潜力的平台技术，但其在大型动物模型中的长期安全性和疗效仍需进一步验证。

---

## 42. 含氮废物清除受损促进肝细胞癌发生。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41512056)
**期刊：** Science advances
**PMID：** 41512056
**DOI：** 10.1126/sciadv.aec0766

### 第一部分 原文与翻译

**英文原标题：** Impaired nitrogenous waste clearance promotes hepatocellular carcinoma.

> **英文摘要：**
> In mammals, hepatic urea cycle enzymes (UCEs) convert ammonia, the toxic nitrogenous waste, into urea for excretion. In hepatocellular carcinoma (HCC), UCE expression is often heterogeneously repressed, but its role in tumorigenesis is unclear. We show that, as in patients, UCE expression is markedly reduced in multiple HCC mouse models, including those driven by oncogenic c-MET/β-catenin, leading to impaired ammonia clearance, altered amino acid metabolism, and increased pyrimidine synthesis. In contrast, UCE expression is largely preserved in c-MET/sgAxin1 tumors, allowing assessment of the consequences of UCE loss. Silencing individual UCEs increases ammonia burden and accelerates HCC with reprogrammed amino acid and pyrimidine metabolism, supporting a causal role for defective ammonia detoxification in oncogenesis. Notably, dietary protein restriction lowers hepatic ammonia and slows tumor growth. These findings establish a mechanistic link between nitrogen overload and hepatocarcinogenesis and highlight protein restriction as a feasible therapeutic strategy for patients with impaired nitrogenous waste handling.

> **中文摘要：**
> 在哺乳动物中，肝脏尿素循环酶将有毒的含氮废物氨转化为尿素以排出体外。在肝细胞癌中，尿素循环酶的表达常被异质性抑制，但其在肿瘤发生中的作用尚不明确。我们发现，与患者情况一致，在多种肝细胞癌小鼠模型（包括由致癌性c-MET/β-catenin驱动的模型）中，尿素循环酶的表达显著降低，导致氨清除受损、氨基酸代谢改变以及嘧啶合成增加。相比之下，在c-MET/sgAxin1肿瘤中，尿素循环酶的表达基本得以保留，这使得我们能够评估尿素循环酶缺失的后果。沉默单个尿素循环酶会增加氨负荷，并通过重编程氨基酸和嘧啶代谢加速肝细胞癌的发展，这支持了氨解毒缺陷在肿瘤发生中的因果作用。值得注意的是，饮食蛋白质限制可降低肝脏氨水平并减缓肿瘤生长。这些发现确立了氮超载与肝癌发生之间的机制联系，并强调了蛋白质限制对于含氮废物处理受损患者而言是一种可行的治疗策略。

### 第二部分 AI 大师评价

本研究旨在阐明尿素循环酶表达抑制在肝细胞癌发生中的因果作用及机制。研究通过多种小鼠模型、基因沉默及饮食干预，系统论证了氨清除受损导致氮超载，进而重编程氨基酸与嘧啶代谢，驱动肿瘤发生。其创新性在于首次建立了含氮废物清除障碍与肝癌之间的直接机制联系，并提出了限制蛋白质摄入这一具有转化潜力的治疗策略。局限性在于研究主要基于小鼠模型，其在人体内的确切疗效与安全性尚需临床验证，且对代谢重编程下游的具体致癌信号通路探索可进一步深入。

---

## 43. 新一代JAK抑制剂在骨髓增殖性肿瘤治疗中的应用。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41511882)
**期刊：** Blood
**PMID：** 41511882
**DOI：** 10.1182/blood.2025028645

### 第一部分 原文与翻译

**英文原标题：** Next-Generation JAK Inhibitors in the Treatment of Myeloproliferative Neoplasms.

> **英文摘要：**
> JAK inhibitors have changed the treatment landscape of myeloproliferative neoplasms, graft-versus host and several autoimmune conditions. While approved JAK inhibitors generally target the JAK2 kinase domain, and several also the JAK1 kinase domain in active form (type I inhibition), new inhibitors have progressed to clinical trials that either exhibit a type II mechanism of inhibition of the kinase domain in an inactive state or that target the pseudokinase domain with potential preference or specificity for the JAK2 V617F mutant. This is the most prevalent mutant in myeloproliferative neoplasms. An ideal inhibitor would target persistently activated JAK2 in MPNs, eradicate the clone or induce deep molecular remission in addition to clinical and hematological remission and spare wild type JAK2 that is critical for hematopoiesis and immune response. We discuss perspectives of these and other modes of JAK inhibition and primary as well as secondary/exploratory study endpoints in clinical trials design, along with potential biomarker correlates to evaluate potential efficacy of the next generation versus conventional JAK inhibitors.

> **中文摘要：**
> JAK抑制剂已经改变了骨髓增殖性肿瘤、移植物抗宿主病以及多种自身免疫性疾病的治疗格局。已获批的JAK抑制剂通常靶向JAK2激酶结构域，其中一些也靶向活性形式的JAK1激酶结构域（I型抑制）。而新一代抑制剂已进入临床试验阶段，它们或通过II型抑制机制作用于非活性状态的激酶结构域，或靶向假激酶结构域，并可能对JAK2 V617F突变体具有偏好性或特异性。该突变是骨髓增殖性肿瘤中最普遍的突变。理想的抑制剂应能靶向骨髓增殖性肿瘤中持续激活的JAK2，在实现临床和血液学缓解的同时，清除克隆或诱导深度分子缓解，并且不伤害对造血和免疫反应至关重要的野生型JAK2。我们讨论了这些及其他JAK抑制模式的前景，以及临床试验设计中主要和次要/探索性研究终点，同时探讨了用于评估新一代与传统JAK抑制剂潜在疗效的相关生物标志物。

### 第二部分 AI 大师评价

本文旨在探讨新一代JAK抑制剂在骨髓增殖性肿瘤治疗中的前景。其核心方法在于开发新型作用机制的抑制剂，包括靶向非活性激酶结构域的II型抑制剂和特异性针对JAK2 V617F突变假激酶结构域的抑制剂。主要发现是，这些新策略旨在更精准地靶向致病性JAK2信号，在追求深度分子缓解的同时，尽可能保留野生型JAK2功能，从而克服现有I型抑制剂的局限性。文章的创新性在于系统梳理了从作用机制到临床试验设计的完整研发逻辑，但其局限性在于，所讨论的多数新药尚处于临床试验阶段，其长期疗效与安全性仍需更多数据验证。

---

## 44. 晚期宫颈癌免疫再挑战应答的时空免疫决定因素。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41511850)
**期刊：** Cancer discovery
**PMID：** 41511850
**DOI：** 10.1158/2159-8290.CD-25-0467

### 第一部分 原文与翻译

**英文原标题：** Spatiotemporal Immune Determinants of Response to Immune Rechallenge in Advanced Cervical Cancer.

> **英文摘要：**
> Although immune checkpoint inhibitors (ICIs) show durable responses in various cancers, relapse remains common. The efficacy of retreatment with ICIs is controversial. We conducted a multicenter, single-arm, phase 2 trial (NCT05824468) including 30 advanced cervical cancer patients that progressed on or after prior ICI therapy. Participants received a combined regimen of zimberelimab and lenvatinib (immune rechallenge). Single-cell multi-omics analysis of sequential biopsies of relapsed tumors and blood samples showed immune rechallenge induced a more cytotoxic phenotype in CD8+T cells in responders, while an NK-like CD8+T and progenitor-exhausted CD8+T phenotype in the blood of non-responders. In tumor, responders showed more effector memory CD8+T cells and reduced exhausted CD8+T cell post-treatment. A population of CD45+CD3+Lyz+dyad cells, composed of T cells and myeloid cells, was correlated with clinical benefit. Our findings proved immune rechallenge could be an effective treatment for patients with advanced cervical cancer who progressed on or after prior ICIs therapy.

> **中文摘要：**
> 尽管免疫检查点抑制剂（ICIs）在多种癌症中显示出持久的应答，但复发仍然常见。再次使用ICIs治疗的疗效存在争议。我们进行了一项多中心、单臂、II期临床试验（NCT05824468），纳入了30例在既往ICI治疗期间或之后发生进展的晚期宫颈癌患者。受试者接受了zimberelimab和乐伐替尼的联合方案（免疫再挑战）。对复发肿瘤和血液样本的连续活检进行的单细胞多组学分析显示，免疫再挑战在应答者的CD8+T细胞中诱导了更具细胞毒性的表型，而在无应答者的血液中则诱导了NK样CD8+T和祖细胞耗竭CD8+T表型。在肿瘤中，应答者治疗后显示出更多的效应记忆CD8+T细胞和减少的耗竭CD8+T细胞。一个由T细胞和髓系细胞组成的CD45+CD3+Lyz+双联细胞群体与临床获益相关。我们的研究结果证明，对于在既往ICI治疗期间或之后发生进展的晚期宫颈癌患者，免疫再挑战可能是一种有效的治疗方法。

### 第二部分 AI 大师评价

本研究旨在探索免疫检查点抑制剂（ICI）治疗失败后，晚期宫颈癌患者接受“免疫再挑战”（联合PD-1抑制剂和乐伐替尼）的疗效及免疫应答的时空动态。研究采用前瞻性II期临床试验设计，并结合单细胞多组学技术对治疗前后的肿瘤和血液样本进行深度分析。核心发现是揭示了应答者与非应答者之间CD8+T细胞表型在肿瘤微环境和外周血中的关键差异，并鉴定出一个与临床获益相关的独特免疫细胞亚群（CD45+CD3+Lyz+双联细胞）。其创新性在于首次在宫颈癌中系统描绘了免疫再挑战的免疫学机制，为精准筛选潜在获益人群提供了线索；局限性在于其为单臂II期研究，样本量有限，且联合方案中乐伐替尼的贡献需进一步剖析。

---

速递结束，祝您工作愉快！